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Abstract
Flanigan, Timothy James. Ph.D. The University of Memphis. August, 2011.
Anxiety-like behavior in C57BL/6J and DBA/2J mice: Pharmacological characterization
of the elevated zero maze and the influence of age-related differences on behavior. Major
Professor: Melloni N. Cook, Ph.D.
Anxiety disorders affect a significant proportion of the population and can be debilitating
in some circumstances. The exact etiology of these disorders remains to be determined
and animal models are an important part of that effort. The elevated zero maze, a
behavioral measure of anxiety, was introduced as an alternative to the popular elevated
plus maze. While the elevated zero maze has been pharmacologically validated in rats,
the available data in mice is more limited. Similarly, the data available on anxiety-like
behavior in adolescent mice lacks breadth despite considerable evidence suggesting that
developmental processes during this period play a role in the etiology of anxiety
disorders. In order to extend the available pharmacological data on the elevated zero
maze and clarify age-related differences in anxiety-like behavior, three experiments using
C57BL/6J and DBA/2J mice were performed. Experiments 1 and 2 examined the effects
of chlordiazepoxide and a serotonin norepinephrine reuptake inhibitor on anxiety-like
behavior in these strains. Experiment 3 examined age-related differences between these
strains in anxiety like behavior during periadolescence, adolescence, and late
adolescence. Anxiety-like behavior was found to vary with strain, task, drug, and age.
These data extend our knowledge of baseline behavior in these stains and extend the
foundation upon which to understand the etiology and treatment of anxiety disorders.
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Anxiety-Like Behavior in C57BL/6J and DBA/2J Mice: Pharmacological
Characterization of the Elevated Zero Maze and the Influence of Age-Related
Differences on Behavior.
It is estimated that each year 40 million adults in the United States suffer from
anxiety disorders, presenting a significant burden to both patients and society as a whole
(NIMH, 2007). Included in the class of anxiety disorders are: panic disorder, obsessivecompulsive disorder, post-traumatic stress disorder, social phobia, specific phobias, and
generalized anxiety disorder (NIMH, 2007). While the symptoms of these disorders vary
widely both between and within disorders, they all share the common attribute of being
characterized by excessive, irrational fear and worry (NIMH, 2007).Though the exact
causes of these disorders are not clear, overarching estimates based on twin and adoption
studies reveal that approximately 30% of the variability in anxiety traits can be explained
by genetic factors, with estimates of heritability between .3-.5 (Clement et al., 2002).
This moderate heritability suggests that these disorders are complex traits involving
multiple, interacting genetic factors and experiential factors. To date, a diathesis-stress
model has largely been used to explain their etiology. Briefly, this model suggests that
some individuals have genetic/ biological traits rendering them vulnerable to the negative
effects of stress, and if a sufficient stressor or series of stressors are experienced, a
pathological state may then ensue. A large body of literature has documented the effects
of various stressors and biological factors on the development of anxiety disorders in
humans and anxiety-like behavior in animal models (for reviews see: Lesch, 2001;
Clement et al., 2002; Finn et al., 2003; Gordon and Hen, 2004; Murray et al., 2009).
However, our knowledge of the biology and experiential components of anxiety disorders
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remains incomplete, and animal models continue to be an important element in furthering
our understanding.
Numerous animal models of anxiety-like behavior are available, and have been
useful in the study of the biology and pharmacology of anxiety-like traits. The vast
majority of these models were developed using rats. However, the use of mice in
neuroscience research has become more widespread as they offer a greater opportunity to
exploit genetic models. While many of the behavioral models developed for rats have
been successfully „shrunken‟ down for use with mice, more pharmacological data on
these models is available from rats than mice. As has been pointed out many times in the
literature, mice are not simply little rats and considerable ethological and biological
differences exist. Further, pharmacological research using mice has largely been
performed using outbred strains, thereby reducing the range of conclusions that might be
drawn from these investigations and limiting the ability to make assertions about the role
of genetics in the phenomena under study (Taft et al., 2006). Despite their limited
employment, inbred strains of mice provide a convenient tool for genetic research, and
they have been shown to vary on a number of important traits including baseline behavior
(e.g., Cook et al., 2001; Liu and Gershenfeld, 2003), response to antidepressant drugs
(Crowley et al., 2005), monoamine concentrations in the brain (Jones et al., 1996), and
structure of proteins involved in serotonin neurotransmission (Hackler et al., 2006).
Additionally, the screening of inbred mouse strains is critical for the detection of
background effects that often influence the interpretation of studies using transgenic mice
(Crawley et al., 1997). Thus, a basic but necessary step towards fully utilizing the wealth
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of murine genetic models in anxiety research is to more fully characterize these
behavioral models using inbred strains of mice.
Towards this aim, three experiments were performed using C57BL/6J (B6) and
DBA/2J (D2) mice. Since its introduction in 1994 (Shepherd et al., 1994), the elevated
zero maze (EZM) has garnered considerable use as a behavioral model of anxiety, and
while it has been pharmacologically validated using rats, the extent of available
pharmacological data on mice is limited. Therefore, the acute effects of a classical
benzodiazepine, chlordiazepoxide (CDZ) on behavior in the EZM were examined.
Additionally, very few antidepressants have been examined in the EZM despite their
frequent use in the treatment of many anxiety disorders. Thus, the behavioral effects of a
common serotonin norepinephrine reuptake inhibitor (SNRI) were examined as well.
(The drug used was acquired from the pharmaceutical company holding rights to this
drug, and a contractual agreement requires the pharmaceutical company to be allowed to
review all presentations and publications of experiments using the drug provided.
Unfortunately, this company collapsed during the recent economic crisis, and we were
unable to meet our obligations. Therefore, this drug will be referred to as „SNRIX‟ in
order to maintain confidentiality until said review or release from the agreement can be
obtained.) Lastly, there is considerable evidence that anxiety traits and the propensity
towards the development of anxiety disorders is shaped in early development and
adolescence (vide infra), but the data on anxiety-like behavior in young mice is lacking as
compared to that available in rats. Hence, the behavior of young mice in a number of
anxiety-related models including the EZM was examined.
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Pharmacological Characterization of the Elevated Zero Maze
All currently available rodent models of anxiety examine an animal‟s behavior in
response to an aversive stimulus or situation. The conditioned models of anxiety
normally use some noxious stimulus such as electric shock, while the unconditioned
models of anxiety examine rodents‟ natural tendency to explore a novel environment
while avoiding situations that might be potentially dangerous (e.g., open/unprotected
spaces, unfamiliar foods, etc.) Of the available unconditioned models, the elevated plusmaze (EPM) is one of the most commonly used. The EPM consists of two alley-ways
arranged perpendicularly at their center creating four arms and a central square. Two of
these arms are enclosed by walls while the other two remain open. Generally rodents will
explore both enclosed and open arms of the maze but spend a great deal more time in the
enclosed arms, and time spent in the open versus closed arms and entries into the open
arms have been pharmacologically validated as measures of anxiety-like behavior.
However, there is ambiguity in interpreting time spent in the center intersection of the
maze. To address this problem, Shepherd and colleagues (1994) developed the EZM.
The EZM consists of a circular runway with alternating open and closed
quadrants. The circular design eliminates the ambiguity of the central square in the EPM
and allows for uninterrupted ambulation, which might provide a more sensitive measure
of anxiety-like behavior (Shepherd et al., 1994). It was initially shown that diazepam and
CDZ decreased anxiety-like behavior in rats, while the anxiogenic compound 1-(mchloro-phenyl)piperazine (mCPP) increased anxiety-like behavior (Shepherd et al.,
1994). Since that time, a number of benzodiazepines at various doses have been shown to
have an anxiolytic effect in rats (see Table 1). On the other hand, the initial adaptation of

4

the EZM for mice was used to examine induced mutations (e.g., Heisler et al., 1998), and
only later were the effects of classical anxiolytic (Bilkei-Gorzo et al., 2002) and
anxiogenic (Bilkei-Gorzo et al., 2004) compounds demonstrated. Still, the range of drugs,
doses, and mouse strains examined remains constricted (see Table 2). Further, only a few
reports are available on the effects of antidepressant medications in the EZM in rats or
mice (see Tables 1 and 2) despite these medications being the most common treatment
for many anxiety disorders (Dulawa et al., 2004).

5

Table 1. Effects of acute administration of standard anxiolytic and anxiogenic drugs in rats on the elevated zero-maze

Drug
Anxiolytics
alprazolam

Strain

Dosages Tested

Open
Time

SpragueDawley

.005, .05,
.5 mg/kg IP

.005↓;
.05, .5 NE

CDZ

SpragueDawley

.5, 1, 2 mg/kg SC

1, 2 ↑

2.5, 5, 10 mg/kg IP

5, 10 ↑

2.5, 5 ↑

6 mg/kg SC
10 mg/kg PO

↑
↑

NE
↑

.25, .5, 1 mg/kg IP

Wistar
diazepam

Charles
Foster
SpragueDawley

Wistar

lorazepam

SpragueDawley

Activity
.005 ↓;
.05, .5 NE

LAT

Head
Dip

Stretch
Attend

NE

Bentué-Ferrer
et al., 2001

.5, 2 ↑

.5, 2 ↓

NE
↑

↓
↓

.5, 1 ↑

.5, 1 ↑

NE

.125, .25,
.5 mg/kg SC
.5 mg/kg SC

.5 ↑

.25, .5 ↑

.5 ↓

↑

↑

↓

1, 2 mg/kg

↑

2↑

NE

.25, .5, 1,
2 mg/kg SC

≥ .5 ↑

NE

↓

.015 mg/kg IP

↓

NE
NE
↓

↓

Reference

Shepherd et al.,
1994
Steckler et al.,
2005
Weiss et al., 1998
Cryan et al., 2004
Ramanathan et al.,
1998
Shepherd et al.,
1994
Shepherd et al.,
1996
Frankowska et al.,
2007
Matto et al., 1997

Bentué-Ferrer
et al., 2001
(Table Continues)

6

Table 1. Effects of acute administration of standard anxiolytic and anxiogenic drugs in rats on the elevated zero-maze
Open
Time
NE

Activity

LAT
NE

Head
Dip
NE

Stretch
Attend
NE

Reference
Matto et al., 1997

Drug
buspirone

Strain
Wistar

Dosages Tested
.04, .2, 1,
5 mg/kg SC

desipramine

Wistar

10, 20 mg/kg IP

NE

↓

NE

NE

NE

Pähkla et al., 2000

fluoxetine

Wistar

5, 10 mg/kg IP

NE

10 ↓

NE

10 ↓

NE

Pähkla et al., 2000

SpragueDawley
Wistar

.3 mg/kg IP

↓ (NS)

↓ (NS)

.1, .5, 1,
1.5 mg/kg IP
.5, 1.5 mg/kg IP

NE

NE

Bentué-Ferrer
et al., 2001
Matto et al., 1997

.25, .5, 1 mg/kg SC

.5, 1 ↓

Anxiogenics
DMCM

mCPP

SpragueDawley

↓

↓

↓
1.5 ↓

↑

↑

↓
1↓

Pähkla et al., 2000
.5, 1 ↑

Shepherd et al.,
1994

For the behavioral measures (open time, activity, latency [LAT], head dip, and stretch attend), doses producing observed effect are
reported where the effect was dose dependent. Blank cells indicate that the measure was not reported by the authors. Open time refers
to time spent in open quadrants of the maze (percentage or actual as reported by authors). Activity refers to locomotor activity in the
maze as reported by authors. Latency (LAT) refers to latency to first enter an open quadrant of the maze. Head dip refers to
observations of the animal dipping its head over the edge of the open quadrants of the maze. Stretch attend refers to observations of
animals adopting a stretched-attend posture, typically defined as an elongated posture with the snout stretched forward. CDZ =
chlordiazepoxide, DMCM = methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, mCPP = m-chlorophenyl-piperazine, IP =
intraperitoneal injection, SC = subcutaneous injection, PO = per os administration, ↑ = increase in measure, ↓ = decrease in measure,
NE = no effect, (NS) = large observed effect but did not reach statistical significance.
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Table 2. Effects of standard anxiolytic and anxiogenic drugs in mice on the elevated zero-maze

Drug
Anxiolytics
alprazolam

Strain

Dosages Tested

Open
Time

BALB/c

1 µg ICV

↑

CDZ

BALB/c

30, 56 µg ICV
3, 10, 30 µg ICV
10 mg/kg PO

56 ↑
30 ↑
↑

C57BL/6J

5, 10, 20 mg/kg IP

DBA/2J

diazepam

buspirone

ACT

LAT

Head
Dip

Stretch
Attend

Reference
Ring et al., 2006

NE
↓

↑

↓

Leonard et al., 2008
Malberg et al., 2007
Mombereau et al., 2004

20 ↓

NE

NE

20 ↓

Mathiasen et al., 2008

5, 10, 20 mg/kg IP

NE

NE

NE

20 ↓

Mathiasen et al., 2008

NMRI

5, 10, 20 mg/kg IP
5, 10, 20 mg/kg IP

5↑
10, 20 ↑

5↓

5, 10 ↑

10, 20 ↓

Mathiasen et al., 2008
Troelsen et al., 2005

OF1

10 mg/kg PO
10 mg/kg PO

↑
↑

↑
↑

↓
↓ (NS)

↑
NE

↓
↓

Cryan et al., 2004
Jacobson and Cryan,
2008

C57BL/6J

1 mg/kg IP
2 mg/kg IP

↓

↑

↑
↑

Bilkei-Gorzo et al., 2002
Bilkei-Gorzo et al., 2004

DBA/2J

2 mg/kg IP

↑

NE

C57BL/6J

1 mg/kg IP

↑

NE

Bilkei-Gorzo et al., 2004
↓

Bilkei-Gorzo et al., 2002
(Table Continues)
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Table 2. Effects of standard anxiolytic and anxiogenic drugs in mice on the elevated zero-maze

Drug
amitriptyline

Strain
NMRI

Dosages Tested
.3, 1, 3, 10 IP
10 mg/kg PO 21 days

Open
Time
NE
NE

desipramine

129SvEv X
C57BL/6

12.5 mg/kg IP

NE

citalopram

NMRI

5, 10, 20,
40 mg/kg IP
10 mg/kg PO 21 days

NE

NE

NE

NE

NE

NE

NE

NE

NE

NE

ACT
NE
NE

LAT
NE
NE

Head
Dip
NE
NE

Stretch
Attend
NE
NE

Reference
Troelsen et al., 2005

NE

NE

NE

Gur et al., 2007

Troelsen et al., 2005

fluoxetine

NMRI

1, 3, 10, 30 mg/kg IP

NE

NE

NE

NE

NE

Troelsen et al., 2005

paroxetine

NMRI

1, 3, 10, 30 mg/kg IP

NE

NE

NE

NE

NE

Troelsen et al., 2005

duloxetine

NMRI

1, 3, 10, 30 mg/kg IP
10 mg/kg PO 21 days

NE
↑

NE
↑

10 ↑
NE

10 ↑
↑

NE
↓

Troelsen et al., 2005

venlafaxine

NMRI

3, 10, 30,
60 mg/kg IP

NE

NE

NE

NE

NE

Troelsen et al., 2005

reboxetine

NMRI

1, 3, 10, 30 mg/kg IP
10 mg/kg PO 21 days

3, 10 ↓
NE

1, 3 ↓
NE

NE
NE

NE
NE

NE
NE

Troelsen et al., 2005

(Table Continues)
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Table 2. Effects of standard anxiolytic and anxiogenic drugs in mice on the elevated zero-maze.

Drug
Anxiogenics
mCPP

Strain

Dosages Tested

Open
Time

C57BL/6J

.5 mg/kg IP

NE

NE

↑

Bilkei-Gorzo et al., 2004

DBA/2J

.5 mg/kg IP

↓

↓

NE

Bilkei-Gorzo et al., 2004

ACT

LAT

Head
Dip

Stretch
Attend

Reference

All effects refer to acute administration unless otherwise noted. For the behavioral measures (open time, activity [ACT], latency
[LAT], head dip, and stretch attend), doses producing observed effect are reported where the effect was dose dependent. Blank cells
indicate that the measure was not reported by the authors. Open time refers to time spent in open quadrants of the maze (percentage or
actual as reported by authors). Activity (ACT) refers to locomotor activity in the maze as reported by authors. Latency (LAT) refers to
latency to first enter an open quadrant of the maze. Head dip refers to observations of the animal dipping its head over the edge of the
open quadrants of the maze. Stretch attend refers to observations of animals adopting a stretched-attend posture, typically defined as
an elongated posture with the snout stretched forward. CDZ = cholrdiazepoxide, mCPP = m-chlorophenyl-piperazine, ICV =
intracerebroventricular injection, IP = intraperitoneal injection, PO = per os administration, ↑ = increase in measure, ↓ = decrease in
measure, NE = no effect, (NS) = large observed effect but did not reach statistical significance.
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Noting these limitations, two experiments were performed using B6 and D2 mice.
The B6 and D2 strains were selected as they are among the most widely available and
thoroughly phenotyped, making them excellent reference populations. Additionally, these
strains have been shown to differ in baseline behavior on measures thought to reflect
aspects of depression (Alcaro et al., 2002; Crowley et al., 2005) and anxiety (Cook et al.,
2001; Wahlsten et al.; 2003), as well as in response to treatment with antidepressant
agents (Liu et al., 2001; Lucki et al., 2001; Crowley et al., 2005).
Experiment 1. At the conception of this experiment, the effects of CDZ in mice on
the EZM had only been reported in the outbred mouse strains, OF1 (Cryan et al., 2004)
and NMRI (Troelsen et al., 2005), and the inbred strain, BALB/c (Mombereau et al.,
2004; Malberg et al., 2007). Thus, we thought that it would be beneficial to examine the
effects of CDZ in B6 and D2 mice. Since that time, Mathiasen et al. (2008) have reported
on the effects of CDZ in these strains on the EZM. However, there are some peculiarities
to their observations. First, it is notable that, at baseline, B6 mice displayed greater
anxiety-like behavior than D2 mice, which is contrary to strain differences reported in
most studies (e.g., Tarantino et al., 2000; Tang et al., 2002; Milner and Crabbe, 2008).
Second, the only effect of CDZ on anxiety behavior observed was an anxiogenic effect in
B6 mice at the 20 mg/kg dose. Therefore, to clarify and extend the available data, the
acute effects of three doses of CDZ (2.5, 5, and 7.5 mg/kg) were examined in the EZM.
Considering the report of Mathiasen (2008), it was difficult to predict the direction of the
effect, if any, that CDZ would have had here. However, in view of the typical effects of
the benzodiazepines, it was expected to elicit an anxiolytic response.
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Experiment 2. In addition to the limited characterization of the effects of
antidepressants in the EZM, many of such studies have excluded key aspects of the
clinical manifestations of these disorders. For example, the prevalence of anxiety and
depressive disorders is far greater in women than in men (Anisman and Matheson, 2005;
Toufexis et al., 2006), there is evidence of sex differences in serotonin transmission
(Bagdy, 1998; Jones and Lucki, 2005), and differences in therapeutic efficacy of
antidepressants (Jones and Lucki, 2005; Duman et al., 2006). However, the majority of
animal research on the behavioral effects of antidepressants has not included females
(Palanza, 2001; Cryan and Mombereau, 2004; Dulawa and Hen, 2005). While female
subjects have been generally left out due to increased complexity and cost associated
with their inclusion, those studies that have made use of female animals have reported
sex differences in baseline behavior (Cryan and Mombereau, 2004), serotonin
transmission (Jones et al., 1996), and behavioral responses to treatment with
antidepressant agents (David et al., 2001; Monleón et al., 2002; Caldarone et al., 2003;
Leuner et al., 2004; Lifschytz et al., 2006) suggesting that the inclusion of females may
provide insight into gender disparities in anxiety-related disorders.
Similarly, the majority of patients experience a 2 – 3 week lag between the onset
of antidepressant use and any therapeutic effects. Yet, most preclinical studies of
antidepressant drugs have only examined the effects of acute administration, and
relatively few behavioral models of depression or anxiety have been responsive to
chronic administration of antidepressants (Brocco et al., 2002; Dulawa and Hen, 2005;
Malberg and Blendy, 2005). This fact presents a number of problems. Foremost, the
validity of these models must be drawn into question, as they fail to incorporate what
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appears to be a central feature of these drugs in clinical populations (i.e., efficacy only
after prolonged administration [Dulawa et al., 2004; Mitchell and Redfern, 2005]). While
an animal model is not expected to incorporate every feature of complex disorders such
as anxiety and depression, extending the use of commonly employed models to include
simple, but commonly neglected, variables could increase our understanding of these
disorders and their treatment.
During the early 1990‟s the „third generation‟ antidepressants were approved for
the treatment of depression in the U.S., and within a decade, these medications accounted
for a considerable proportion of antidepressant drugs prescribed (Hansen et al., 2010;
Vlahiotis et al., 2011). Among these are the serotonin norepinephrine reuptake inhibitors
(SNRIs), which act similarly to the tricyclic antidepressants in that they inhibit both
serotonin and norepinephrine reuptake but have a more favorable side effect profile due
to their greater specificity (Olver et al., 2001). SNRIX was one of the first SNRIs
approved for use and its clinical efficacy in the treatment of depression and anxiety is
well established (Kent, 2000). However, behavioral studies of SNRIX in mice are
relatively limited, and only the acute effects of SNRIX have been examined in the EZM
(Troelsen et al., 2005).
Seeking to address this, we treated male and female B6 and D2 mice with SNRIX
or vehicle for 29 days and then measured behavior on a battery of seven tests. Our
primary interest was the effects of chronic administration of SNRIX on behavior in the
EZM. Therefore, behavior on the EZM was measured on the 30th day following the
initiation of drug treatment. Additionally, noting the general lack of behavioral data on
the effects of SNRIX in mice, animals were put through a testing battery for an additional
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three days. The testing battery used has previously been shown to be an effective high
throughput behavioral screen in a large scale mutagenesis project (Cook et al., 2007) and
allows for a timely survey of a broad range of behaviors. Thus, we hypothesized that this
experimental design would allow us to efficiently detect strain and/ or sex dependent
effects of chronic antidepressant administration if they did exist, while enhancing the
range of available data on the behavioral effects of SNRIX.
Behavioral Characterization of Adolescent Mice
With the major physiological, cognitive, and social changes characteristic of
adolescence, comes an increased occurrence of impulsivity, risk-taking behavior, and
psychopathology. For example, in the U.S., 50% of adolescents have consumed alcohol
and over 30% have used an illicit drug by about age 15 (Johnston et al., 2008).
Additionally, the initial onset of generalized anxiety disorder, panic disorder, and
obsessive compulsive disorder frequently occurs during this time (Lesch, 2001; Grover et
al., 2005; Gregory et al., 2008). In fact, symptoms of depression and/ or anxiety are the
leading reasons for mental health treatment among adolescents, and suicide is the third
leading cause of death among children 15 – 19 years of age (HRSA, 2004).
While there is evidence that the common emergence of mood disorders during
adolescence is related to the physical maturation of the brain (for example see: Casey et
al., 2010), it is also clear that these developmental processes are taking place within the
larger gene X environment interactions that shape both healthy and pathological
outcomes (Leonardo and Hen, 2008; Casey et al., 2010). Hence, it has been proposed that
the gene X environment interactions thought to underlie the etiology of the mood
disorders would be better conceptualized as gene X environment X development

14

interactions (Leonardo and Hen, 2008). In attempting to understand these three-way
interactions, murine models provide convenient means to examine the effects of genetic
and environmental factors; however, the available data on baseline behavioral differences
among juvenile mice is relatively sparse. Further, the data that is available primarily
comes from pharmacological studies examining a wide range of ages, and often baseline
age-related differences are not reported or age groups are analyzed separately.
Noting the limited research in this area, Hefner and Holmes (2007) examined
behavior of male B6 mice at 4, 6, and 8 weeks of age which map onto what has been
termed periadolescence (weaning to approximately 1 week prior to puberty), midadolescence, and late-adolescence, respectively (Adriani et al., 2004). They used three
measures of anxiety-related behavior (fear conditioning, EPM, and open field) and a
measure of depression-like behavior (the forced swim test). They found age-related
differences in fear conditioning, anxiety-like behavior in the open field, and depressionlike behavior in the forced swim test but no differences in anxiety-like behavior in the
EPM. Considering that they found age-related differences in some, but not all, anxietyrelated measures and the possibility that age-related differences could vary with
genotype, we sought to extend this inquiry to include additional measures and an
additional inbred strain. Therefore, the behavior of male B6 and D2 mice beginning at
PND 28, 42, and 56 was examined in a modified version of the testing battery used in
Experiment 2 above.
Experiment 3. The choice of B6 and D2 mice was based on the characteristics
noted previously (Vide Supra). The behavioral battery used was the same as that in
Experiment 2 except startle/prepulse inhibition was excluded in order to allow all animals
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to be tested in a single week. Given that Hefner and Holmes (2007) found the effects of
age to be task specific, we expected that this battery would help clarify the nature of these
differences as it provides two additional tests of anxiety-like behavior and a different test
of depressive-like behavior.
Method
Subjects
B6 and D2 mice (35 to 40 days of age for Experiments 1 and 2; 21, 35, and 49
days of age for Experiment 3) were purchased from the Jackson Laboratory (Bar Harbor,
MN, USA), and housed five per cage in the University of Memphis vivarium. All animals
had access to food and water ad libitum and were maintained on a 12:12 light/dark cycle
with lights on at 06:30 and lights off at 18:30. The average temperature in the vivarium,
to date, is 23º C with humidity varying between 30 and 70%. The number of animals used
in Experiments 1 and 2 are reported in Tables 3 and 4, respectively. A total of 60 mice
(10 per experimental cell) were used in Experiment 3.

Table 3. Number of animals used (n) by strain and CDZ dose in Experiment 1
Strain
C57BL/6J
DBA/2J

Saline
15
10

2.5 mg/kg
10
10

Only males were examined.
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5 mg/kg
10
10

7.5 mg/kg
10
10

Table 4. Number of animals used (n) by strain, sex, and drug dose in Experiment 2
B6
Drug Treatment Male
Saline
9
10 mg/kg
12
30 mg/kg
12

Female
11
11
12

D2
Male
12
11
11

Female
10
12
12

B6 = C57Bl/6J, D2 = DBA/2J.

Procedure
Experiment 1. At PND 60, mice were weighed and placed in a darkened holding
area for at least 30 minutes. After this habituation period mice received an intraperitoneal
(IP) injection of either CDZ (2.5, 5, or 7.5 mg/kg) or saline. Thirty minutes later they
were tested on the EZM.
Experiment 2. At PND 60, animals were weighed and received an injection of
either SNRIX (10 or 30 mg/kg IP) or saline, once daily for 29 days. At PND 90, animals
began four days of behavioral testing. Behavioral testing was conducted in the following
order: Day 1: elevated zero-maze; Day 2: open field and hotplate; Day 3: light/dark,
startle, and fear conditioning training; Day 4: testing of contextual and cued conditioning,
and tail suspension.
Experiment 3. Animals were allowed one week to habituate to the vivarium
before behavioral testing. At PND 28, 42, or 56 (4wk, 6wk, 8wk, respectively) animals
began a four day battery of testing conducted in the following order: Day 1: elevated
zero-maze; Day 2: open field and hotplate; Day 3: light/dark and fear conditioning
training; Day 4: testing of contextual and cued conditioning, and tail suspension.
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For all experiments, testing was conducted so that animals belonging to each
experimental cell were represented throughout each testing period. All apparatus were
cleaned with 70% isopropanol between mice and allowed to dry. For Experiments 2 and
3 all animals were tested using each measure in the same order and allowed a minimum
habituation period of 30 min before each test.
Drugs
CDZ was purchased from Sigma Chemicals (St. Louis, MO, USA). The chosen
doses are largely based on those previously shown to have an anxiolytic effect in mice on
the EPM (Lister et al., 1987; Raupp et al., 2008; Clément et al., 2009; Paterson et al.,
2010) but below those producing sedation (Fielding and Hoffman, 1979). SNRIX was
provided by the pharmaceutical company holding rights to this drug. Dosages of 10 and
30 mg/kg were chosen as approximations of both those reported in the literature to be
behaviorally effective in mice and those shown to produce serum levels within the
therapeutic range when administered chronically (Ahern et al., 2006.) Dosages were
calculated as the weight of the salt. Both drugs were dissolved in .9% saline (w/v) and
administered in an injection volume of 10 ml/kg. Control animals were injected with an
equivalent volume of .9% saline alone.
Behavioral Testing and Apparatus
Elevated Zero Maze. Elevated zero mazes were manufactured by AccuScan
Instruments (Columbus, OH, USA). The apparatus is an elevated black circular platform
consisting of open and closed quadrants. Because we are interested in the avoidance of
open versus closed areas and to minimize differences in light intensity between the open
and closed quadrants, the closed quadrants are enclosed by clear acrylic walls 28.5 cm in
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height (Martínez et al., 2002). The closed quadrants are each equipped with infrared light
beams allowing the amount of time spent and activity in the closed quadrants to be
monitored. The open quadrants have a slightly raised Plexiglas lip to prevent the mice
from falling off of the maze. The zero-maze has been described in detail elsewhere (Cook
et al., 2001).
Mazes were separated from one another by solid partitions such that each maze is
equidistant from three extra-maze walls. A greater range of behavior is generally
displayed when testing is performed under dim and/or red light (Kalinichev et al., 2002;
Tang et al., 2002). Therefore, like others (Parfitt et al., 2007), each maze was dimly lit by
a 15W red light bulb suspended approximately 125 cm above the maze, providing an
average illumination of 14 lx at the level of each quadrant.
On the day of testing, animals were acclimated to a darkened holding area prior to
testing. Test duration was five minutes. Animals were placed in a closed quadrant to
begin the test period. Latency to enter an open quadrant, total time spent in open and
closed quadrants, and activity in the closed quadrants was recorded. Activity levels can
vary greatly because their measurement is a function of time spent in the closed
quadrants; therefore, we evaluate activity as beam breaks per second spent in the closed
quadrants.
Open Field. The open field arenas consist of a Plexiglas open field insert (24.13
cm x 45.72 cm) in a HamiltonKinder SmartFrameTM system (HamiltonKinder, Poway,CA,
USA). The system uses two 4x8 photobeam arrays, one to detect horizontal movements
and one to detect vertical movements. The average illumination of the arena is 60 lx.
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Animals were placed in the center of the open field to begin the 20 min test
period. Based on the position and sequence of beam breaks during the test period the
following measures were evaluated: distance traveled , rears, and percentage of time
spent in the center of the arena (defined as the 9 x 10 cm area located 15 cm from front
and back walls and 4.5 cm from the left and right walls of the arena), percentage of time
spent in the corners of the arena, percentage of total distance traveled occurring in the
center of the arena, and habituation ratio (i.e. the ratio of distance traveled during the last
five minutes of testing to the sum of the distance traveled during the first and last five
minutes of testing.) At the end of the testing period animals were returned to their home
cage until the next test.
Hotplate. A hotplate algesia meter (Model 39) manufactured by IITC Inc.
(Woodland Hills, CA, USA) was used. The unit has an anodized aluminum plate
measuring 27.94 X 26.67 X 1.91 cm. A heat sink compound (Radio Shack® Cat no. 2731372) was used between the hotplate surface and the aluminum plate to facilitate an even
distribution of heat. The aluminum plate was held in position with binder clips. A small,
bottomless translucent grey Plexiglas enclosure (8.5 X 6.5 X 8.5 cm) was used to confine
animals to the center of the aluminum plate.
All overhead lights were turned off 30 minutes prior to testing. A small desk lamp
directed away from the algesia meter and a mirror placed behind the hotplate was used to
facilitate observations of the animal. The hotplate was heated to 52° C, and a surface
thermometer was used to verify the temperature throughout the test. The mouse was
placed in the Plexiglas enclosure in the center of the hotplate and observed for pain
responses associated with the hind paws indicated by licking, shaking, or jumping. Once
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a pain response was displayed, the animal was immediately removed from the hotplate
and the latency recorded. If the animal did not show a pain response within 20 seconds,
it was immediately removed and the test discontinued. For those animals that did not
respond, the maximum latency of 20 seconds was assigned.
Light-Dark. The light dark apparatus is identical to the apparatus used for open
field only different inserts are used. The light/dark inserts are of the same overall
dimensions, except that one half is made of clear Plexiglas and the other half is made
black Plexiglas. The two halves are separated by a manual guillotine door that allows the
animal to move freely between the two compartments when removed. The light half of
the light/dark enclosure is illuminated by a 15 W light bulb approximately 48 cm above
the chamber providing an average illumination of 33 lx in the light half and 1 lx in the
dark half of the apparatus.
Overhead lights were turned off thirty minutes prior to testing. To begin the 10
minute test period, animals were placed in the light half of the box and the guillotine door
was then removed. The distance traveled in the either side of the box, percentage of time
spent in the light side of the apparatus, and the percentage of the total distance traveled
that occurred in the light side were measured. At the end of the test period animals were
returned to their home cages.
Acoustic Startle/Prepulse Inhibition. A HamiltonKinder SM100 Startle Monitor
was used. The system consists of base plate, mouse sensing plate, mouse restrainer, and
Newton impulse Calibrator (calibrated in newtons) enclosed in a sound attenuating
cabinet. The cabinet measures 35.56 X 27.62 X 49.53 cm and has 35 db of attenuation.
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The system is designed to provide +/- 1 db accuracy on a scale from 57-120 db and to
minimize variability between test chambers (<1 db; www.hamiltonkinder.com.)
Animals were placed in the startle chamber with a 65 db background white noise
and allowed to habituate for two minutes. The two minute period was followed by 55
pseudo-random trials separated by 15 second intertrial intervals. A 120 db white noise
burst was used as the acoustic startle stimulus. Pre-pulses were 70, 80, and 85 db white
noise bursts lasting 20 ms which precede the startle stimulus by 100 ms. Startle response
to the startle stimulus and to each of the pre-pulse db levels was measured. Pre-pulse
inhibition was calculated using the following formula [100- (pre-pulse startle/acoustic
startle) x 100]. Animals were returned to their home cage following testing.
Fear Conditioning. The Hamilton-Kindler SmartFrame system was used in
conjunction with fear conditioning inserts (24.13 cm x 22.86 cm). The inserts have a grid
floor connected to a shock generator and the top of the box includes a speaker attached to
a sound generator.
Training. Animals were placed in the fear conditioning chambers and allowed to
habituate for 2.5 minutes. Animals were then presented with three pairings of an 85 db
tone and a 0.36 mA foot shock separated by a 2.5 minute intertrial interval. The tone was
presented for 30 seconds and the shock was administered during the last 2 seconds of the
tone. Because this test is automated, beam breaks were measured in 30 second intervals.
The average number of beam breaks per 30 second interval for the first two minutes of
training was used as an indication of baseline activity. The ratio of baseline activity to the
number of beam breaks during the 30 second interval following the final tone + shock
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pairing (suppression of activity by training) was used as an indicator of the degree to
which the training procedure suppressed activity.
Contextual Conditioning. On the day following the training session, animals were
placed back into the same chambers where they underwent training. During this 6 minute
session, activity (beam breaks) per 30 second bin was measured and compared to activity
during the habituation period on the training day. The ratio of baseline activity to activity
during re-exposure to the training context was used as a measure of conditioning to the
context.
Cued Conditioning. Approximately 2 hr later, behavior was tested in an altered
context. The fear conditioning chambers were altered by placing a plastic grey tile over
the grid floor, placing a black Plexiglas insert over the walls of the chambers, and
attaching a small cup containing orange oil diluted in water in the upper corner of the
box. Animals were allowed to explore the altered environment for 2.5 minutes, after
which time, the conditioned stimulus (tone) was presented for 2.5 minutes. Activity
(beam breaks) was measured in 30 second bins. Activity suppression during presentation
of the tone was evaluated relative to activity during the habituation period in the altered
context. Animals were returned to their home cage following each session.
Tail suspension. A tail suspension apparatus manufactured by MedAssociates
(St. Albans, VT, USA) was used. Each unit consists of a linear load cell with an amplifier
and filter connected to a transducer. The units are each enclosed by an open faced
cubicle.
All animals were weighed to the nearest .1 g prior to tail suspension testing. The
body weights were entered into the tail suspension program, which automatically
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calculates a threshold for force of movement for each animal. At the start of the session
each animal‟s tail was taped to the transducer. Force of movement was recorded for six
minutes. The session was divided into twelve 30 second intervals, and time spent above
threshold was examined for the entire session and each interval. Animals were observed
during testing and tail climbing recorded. Those animals that climbed their tails were not
included in the analysis.
Analysis
Experiment 1. Data for the dependent variables were examined using analysis of
variance (ANOVA) with strain and CDZ dose as between subjects variables.
Experiment 2. Data from the light/ dark box and tail suspension test were lost
during the experiment for some animals due to a computer error. The number of animals
missing and the treatment groups to which they belonged is reported along with the
results from these tests. Prior to the analysis of data from these tests, all observations
were coded dichotomously as missing or not. This was then compared to all other
variables in the study via bivariate correlation in order to determine the nature of the
missing data. Significant correlations between missing observations and other variables
are reported along with the results.
Three-way ANOVA using strain, sex, and drug dosage as the between subjects
variables for each independent measure were used to analyze the data. The only
exceptions to this were the analyses of body weight, interval data from the tail suspension
test, and tail climbing behavior. For body weight and tail suspension intervals repeated
measures ANOVA were performed using strain, sex, and drug dosage as between subject
factors and weight or interval as the respective within subjects variable. Data for tail
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climbing during the tail suspension test were coded dichotomously and analyzed using
logistic regression analysis with the independent variables strain, sex, and drug dosage as
predictors.
Experiment 3. Data were analyzed using separate two-way ANOVAs for each
dependent measure with strain and age as between subject factors. Again here, tail
suspension interval data were analyzed using a repeated measures ANOVA.
For all analyses, where significant effects were found (p < .05), post hoc
comparisons were made using Tukey‟s HSD method or analysis of simple effects was
employed, as appropriate. Effect sizes are presented for select variables in the discussion
to aid in the interpretation of the results. All analyses and calculations were performed
using SPSS 11.5 except for calculations of effect size, which was performed using
GPower 3.0.5.
Results
Experiment 1
Upon inspection of the data, we found that some animals‟ measures on latency to
enter an open quadrant and percentage of time in the open quadrants of the maze were
extreme. Two animals‟ latency measures were more than three standard deviations from
the mean (one B6 mouse in the 2.5 mg/kg group and one D2 mouse in the saline group),
and four animals scored more than three standard deviations from the mean on the
percentage of time spent in the open quadrants (one B6 mouse given 2.5 mg/kg, one D2
mouse given 2.5 mg/kg, and two D2 mice in the 7.5 mg/kg group). Therefore, these
animals were considered to be outliers and were not included in the respective analyses.
Data are presented in Table 5.
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Activity in the closed quadrants. ANOVA revealed a significant effect of strain
on activity, F (1, 77) = 3.928, p = .05, with B6 mice being slightly more active than D2
mice (M = 2.54, SD = .41 and M = 2.36, SD = .42, respectively). ANOVA failed to
detect an effect of CDZ or an interaction between strain and CDZ administration, F (3,
77) = 2.033, p = .116, and F (3, 77) = .919, p = .436, respectively.

Table 5. Means and standard errors of measures in the elevated zero maze for
Experiment 1 by strain and drug treatment

Strain
B6
D2
B6
D2
B6
D2

Saline
2.5 mg/kg
5 mg/kg
Activity
2.59 (.11)
2.28 (.13)
2.77 (.13)
2.32 (.13)
2.27 (.13)
2.40 (.13)
Latency (s) to Enter an Open Quadrant
5.97 (2.77)
10.46 (3.57)
4.64 (3.39)
12.30 (3.57)
15.78 (3.39)
13.50 (3.39)
Percentage of Time Spent in the Open Quadrants
24.91 (2.68)
20.12 (3.46)
18.12 (3.28)
12.10 (3.28)
15.40 (3.46)
10.18 (3.28)

7.5 mg/kg
2.53 (.13)
2.47 (.13)
3.05 (3.39)
20.90 (3.39)
29.47 (3.66)
24.11 (3.66)

Animals were administered saline, 2.5, 5, or 7.5 mg/kg chlordiazepoxide thirty minutes
prior to testing. Numbers are means and numbers in parentheses are standard errors of the
means. Activity is measured as beam breaks per second spent in the closed quadrants of
the maze. B6 = C57BL/6J, D2 = DBA/2J

Latency to first enter an open quadrant. ANOVA detected a significant effect
of strain, F (1, 75) = 15.55, p < .001, with B6 mice exhibiting a shorter latency than D2
mice. However, there was no effect of CDZ and no strain by drug treatment interaction, F
(3, 75) = .678, p = .568, and F (3, 75) = 1.233, p = .304, respectively.
Percentage of time spent in the open quadrants. ANOVA revealed a significant
effect of strain, F (1, 73) = 10.88, p = .002, with B6 mice spending more time in the open
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quadrants than D2 mice. Likewise, a significant effect of CDZ was found, F (3, 73) =
4.911, p = .004. See Figure 1, panel A. Post hoc testing indicated that none of the doses
tested differed from saline alone, but animals administered 7.5 mg/kg CDZ spent more
time in the open quadrants of the maze than those given either 2.5 or 5 mg/kg. Examining
the means by strain suggests that the effect of CDZ is largely driven by an effect of 7.5
mg/kg increasing time spent in the open in D2 but not B6 mice. See Figure 1, panel B.
However, the strain by drug treatment interaction was not significant, F (3, 73) = .677, p
= .569. None the less, if the data are analyzed separately by strain an effect of CDZ is
found in D2 mice but not B6 mice (D2 mice: F (3, 33) = 3.44, p = .028; B6 mice: F (3,
40) = 2.207, p = .102).
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Figure 1. Effects of CDZ on the percentage of time spent in the open quadrants of the
elevated zero maze. Data are presented as means ± SEM. A.) Main effect of drug dose.
Groups that do not share a common lower case letter are significantly different at the
level p < .05. B.) The effect of CDZ by dose and strain. The interaction was nonsignificant (F (3, 73) = .677, p = .569).

Experiment 2
Body weight
To determine if drug administration affected animals‟ body weight, weights
during drug treatment at PND 60, 70, 80, and 89, as well as weight prior to tail
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suspension testing on the final day of testing (PND 93) were selected for analysis.
Repeated measures ANOVA did not detect any effects of the drug treatment on body
weight (p > .2 for all; Data not presented)
Elevated Zero Maze
Activity in the closed quadrants. ANOVA revealed a significant main effect of
strain, F (1, 123) = 6.117, p < .05, with B6 mice being more active than D2 mice.
ANOVA failed to detect significant main effects of sex or drug treatment: F (1, 123) =
.045, p = .83, and F (2, 123) = .653, p = .52, respectively. Likewise, ANOVA failed to
detect significant strain x sex, strain x drug treatment, sex x drug treatment, or strain x
sex x drug treatment interactions: F (1, 123) = 1.173, p = .281; F (2, 123) = .829, p = .44;
F (2, 123) = 1.292, p = .279; and F (2, 123) = .393, p = .68; respectively. (See Table 6 for
data.)
Latency to enter an open quadrant. ANOVA revealed a significant main effect
of strain, F (1, 123) = 10.016, p = .002, with B6 mice entering an open quadrant sooner
than D2 mice (M = 4.84, SEM = 1.31, and M = 10.69, SEM = 1.30, respectively).
However, ANOVA failed to detect an effect of sex or drug treatment: F (1, 123) = 050, p
= .82, and F (2, 123) = 1.832, p = .16, respectively. ANOVA revealed a significant strain
x sex interaction, F (1, 123) = 3.953, p = .049. Analysis of simple effects found no
difference between D2 males and females, but B6 females displayed a shorter latency
than B6 males. B6 and D2 males did not differ, but B6 females displayed a shorter
latency than did D2 females. ANOVA did not detect significant strain x drug treatment,
sex x drug treatment, or strain x sex x drug treatment interactions: F (2, 123) = 2.099, p =
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.127; F (2, 123) = .202, p = .82; and F (2, 123) = .422, p = .66; respectively. (See Table 6
for data.)

Table 6. Means and standard errors of measures in the elevated zero maze for
Experiment 2 by strain, sex, and drug treatment
B6
Drug Treatment Male
Activity
Saline
2.22 (.17)
10 mg/kg
2.04 (.15)
30 mg/kg
2.16 (.15)

Female

D2
Male

Female

2.22 (.16)
2.08 (.16)
2.46 (.15)

1.99 (.15)
2.14 (.16)
1.91 (.16)

2.01 (.16)
1.81 (.15)
2.00 (.15)

Saline
10 mg/kg
30 mg/kg

Latency (s) to Enter an Open Quadrant
6.66 (3.57)
2.72 (3.23)
11.84 (3.09)
6.68 (3.09)
4.64 (3.23)
7.03 (3.23)
6.07 (3.09)
2.26 (3.09)
7.06 (3.23)

19.93 (3.38)
8.77 (3.09)
9.50 (3.39)

Saline
10 mg/kg
30 mg/kg

Percentage of Time Spent in the Open Quadrants
16.80 (3.14)
15.88 (2.84)
11.62 (2.72)
19.57 (2.72)
19.22 (2.84)
16.68 (2.84)
16.13 (2.72)
23.09 (2.72)
9.11 (2.84)

15.09 (2.98)
16.24 (2.72)
9.06 (2.72)

Activity is measured as beam breaks per second spent in the closed quadrants. Numbers
in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J.

Percentage of time spent in an open quadrant. ANOVA revealed a main effect
of strain, F (1, 123) = 11.335, p = .001, with B6 animals spending a greater percentage of
time in the open quadrants of the maze. ANOVA failed to detect significant effects of sex
or drug treatment, F (1, 123) = .786, p = .38, and F (2, 123) = 1.935, p = .149,
respectively. Likewise, none of the interactions were found to be significant: strain x sex,
F (1, 123) = .076, p = .78; strain x drug treatment, F (2, 123) = 2.460, p = .090; sex x
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drug treatment, F (2, 123) = .490, p = .61; strain x sex x drug treatment, F (2, 123) =
1.35, p = .36. (See Table 6 for data.)
Open Field
Total distance traveled. ANOVA revealed a significant main effect of strain, F
(1, 123) = 30.006, p < .001, with B6 mice traveling a greater distance than D2 mice.
Likewise, ANOVA revealed a significant effect of sex, F (1, 123) = 6.411, p = .013, with
males traveling a greater distance than females. ANOVA failed to detect a significant
main effect of drug treatment, F (2, 123) = .704, p = .497. However, a significant strain x
sex interaction was found, F (1, 123) = 18.059, p < .001. Analysis of simple effects
revealed that B6 males and females did not differ, but D2 males traveled a greater
distance than D2 females. Further, while B6 females traveled a greater distance than D2
females, B6 and D2 males did not differ. ANOVA failed to detect significant strain x
drug treatment, sex x drug treatment, or strain x sex x drug treatment interactions: F (2,
123) = .413, p = .66; F (2, 123) = .596, p = .55; and F (2, 123) = .623, p = .54;
respectively. (See Table 7 for data.)
Rears. ANOVA failed to detect significant main effects of strain, sex, or drug
treatment: F (1, 123) = 1.537, p = .212; F (1, 123) = .206, p = .65; and F (2, 123) = .653,
p = .52; respectively. However, a significant strain x sex interaction was found, F (1, 123)
= 11.756, p = .001. Analysis of simple effects revealed that B6 females reared more
frequently than B6 males, but D2 males reared more frequently than D2 females.
Likewise, D2 males reared more frequently than B6 males, and B6 females reared more
frequently than D2 females. ANOVA failed to detect significant strain x drug treatment,
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sex x drug treatment, or strain x sex x drug treatment interactions: F (2, 123) = .204, p =
.82; F (2, 123) = .156, p = .86; and F (2, 123) = 1.557, p = .22; respectively. (See Table 7
for data.)

Table 7. Means and standard errors for measures in the open field in Experiment 2
by strain, sex, and drug treatment
B6
Drug Treatment Male
Female
Total Distance (cm) Traveled
Saline
2031.1 (207.7) 2155.0 (187.9)
10 mg/kg
1839.0 (179.9) 2204.4 (187.9)
30 mg/kg
1868.5 (179.9) 1934.0 (179.9)

D2
Male

Female

2010.8 (179.9)
1648.8 (187.9)
1682.4 (187.9)

1012.9 (197.0)
971.8 (179.9)
1166.8 (179.9)

Saline
10 mg/kg
30 mg/kg

Number of rears
106.67 (13.90) 124.00 (12.58)
101.50 (12.04) 144.82 (12.58)
128.42 (12.04) 132.08 (12.04)

125.42 (12.04)
130.91 (12.58)
127.27 (12.58)

100.40 (13.19)
91.25 (12.04)
108.00 (12.04)

Saline
10 mg/kg
30 mg/kg

Habituation Ratio
.442 (.029)
.378 (.026)
.458 (.025)
.362 (.026)
.409 (.025)
.367 (.025)

.417 (.025)
.451 (.026)
.421 (.026)

.379 (.028)
.358 (.025)
.369 (.025)

Saline
10 mg/kg
30 mg/kg

Percentage of Time Spent in Corners
42.09 (1.97)
44.89 (1.78)
38.68 (1.71)
45.70 (1.71)
41.80 (1.78)
37.36 (1.78)
39.90 (1.71)
43.49 (1.71)
40.09 (1.78)

Saline
10 mg/kg
30 mg/kg

Percentage of Distance Traveled Occurring in the Center
39.12 (2.25)
37.77 (2.04)
26.26 (1.95)
16.95 (2.13)
37.41 (1.95)
38.24 (2.04)
25.98 (2.04)
13.65 (1.95)
42.08 (1.95)
34.54 (1.95)
27.90 (2.04)
19.45 (1.95)

29.22 (1.87)
26.79 (1.71)
26.20 (1.71)

Numbers are means. Numbers in parentheses are standard errors. Habituation ratio is the
distance traveled during the last five minutes of testing over the sum of the distance
traveled during the first and last five minutes of testing. B6 = C57Bl/6J, D2 = DBA/2J.
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Habituation Ratio. ANOVA failed to detect a main effect of strain, F (1, 123) =
.054, p = .82. However, a significant main effect of sex was found, F (1, 123) = 18.097, p
< .001, with males demonstrating a greater degree of habituation to the arena than
females. ANOVA failed to detect a main effect of drug treatment, F (2, 123) = .420, p =
.66. Likewise, no significant strain x sex, strain x drug treatment, sex x drug treatment, or
strain x sex x drug treatment interactions were found: F (1, 123) = .043, p = .84; F (2,
123) = .127, p = .88; F (2, 123) = 1.032, p = .36; and F (2, 123) = .114, p = .89;
respectively. (See Table 7 for data.)
Percentage of time spent in the corners of the arena. ANOVA revealed a main
effect of strain, F (1, 123) = 94.476, p < .001, with B6 mice spending a greater
percentage of time in the corners than D2 mice. A main effect of sex was also found, F
(1, 123) = 26.328, p < .001, with males spending a greater percentage of time in the
corners than females. ANOVA failed to detect a significant main effect of drug treatment,
F (1, 123) = .584, p = .58. However, a significant strain x sex interaction was found, F (1,
123) = 35.356, p < .001. Analysis of simple effects revealed that while B6 males and
females did not differ, D2 males spent a greater percentage of time in the corners than did
D2 females. Further, while B6 and D2 males did not differ, B6 females spent a greater
percentage of time in the corners than did D2 females. ANOVA failed to detect
significant strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment
interactions: F (2, 123) = .843, p = .43; F (2, 123) = 1.197, p = .306; and F (2, 123) =
2.430, p = .092; respectively. (See Table 7 for data.)
Percentage time spent in the center of the arena. ANOVA revealed a main
effect of strain, F (1, 123) = 297.257, p < .001, with B6 mice spending a greater
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percentage of time in the center of the arena than D2 mice. Likewise, a main effect of sex
was detected, F (1, 123) = 15.924, p < .001, with males spending more time in the center
than females. ANOVA failed to detect a main effect of drug treatment, F (2, 123) = .217,
p = .81. A significant strain x sex interaction was found, F (1, 123) = 4.584, p = .034.
Analysis of simple effects confirmed that B6 mice of both sexes spent more time in the
center of the arena than did D2 mice of both sexes. Further, while there was no difference
between B6 males and females, D2 females spent more time in the center than D2 males.
ANOVA did not detect a significant strain x drug treatment interaction, F (2, 123) = .048,
p = .953, but the sex x drug treatment interaction was found to be significant, F (2, 123) =
3.475, p = .034. Analysis of simple effects found that among females the drug treatment
had no effect. However, in males, 30 mg/kg increased the amount of time spent in the
center of arena, but 10 mg/kg of the drug had no effect. Further, males and females given
SAL or 10 mg/kg of the drug did not differ, but males given 30 mg/kg spent more time in
the center than did females given the same dose. Additionally, the strain x sex x drug
treatment interaction was found to be significant, F (2, 123) = 4.701, p = .011, see Figure
2. Analysis of simple effects showed that under all treatment conditions B6 mice spent
more time in the center than D2 mice. Among D2 mice, males and females did not differ,
and there was no effect of drug treatment. Among B6 mice administered either saline or
10 mg/kg of the drug, there were no differences between drug treatments or sexes.
However, B6 males administered 30 mg/kg of the drug spent more time in the center than
B6 males administered SAL or 10 mg/kg of the drug, but an opposite relation was seen
among B6 females. Those given SAL or 10 mg/kg of the drug did not differ, but those
given 30 mg/kg spent less time in the center than those given 10 mg/kg.
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Figure 2. The effect of SNRIX on percentage of time spent in the center of the open field
arena by strain, sex, and dose. Data are presented as means ± SEM. Groups that do not
share a common lower case letter are different at the level, p < .05. B6 = C57BL/6J, D2 =
DBA/2J.

Percentage of total distance traveled occurring in the center of the arena.
ANOVA revealed a main effect of strain, F (1, 123) = 200.182, p < .001, with B6 mice
traveling a greater distance in the center than D2 mice. Additionally, the main effect of
sex was significant, F (1, 123) = 29.729, p < .001, with males traveling a greater distance
in the center of the arena than females. ANOVA failed to detect a main effect of drug
treatment, F (2, 123) = 1.203, p = .304. A significant strain by sex interaction was found,
F (1, 123) = 9.916, p = .002. Analysis of simple effects revealed that both B6 males and
females traveled a greater distance in the center than did their respective D2 counterparts.
Further, B6 males and females did not differ, but D2 males traveled a greater distance in
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the center than did D2 females. ANOVA failed to detect significant strain x drug
treatment or sex x drug treatment interactions: F (2, 123) = .750, p = .47, and F (2, 123) =
.510, p = .60, respectively. Likewise, the strain x sex x drug treatment interaction failed
to reach significance, F (2, 123) = 2.411, p = .094. (See Table 7 for data.)
Hotplate
Latency to display hindpaw pain response. ANOVA revealed a main effect of
strain, F (1, 123) = 16.980, p < .001, with B6 mice showing a pain response sooner than
D2 mice. ANOVA failed to detect a main effect of sex or drug treatment: F (1, 123) =
1.306, p = .255, and F (2, 123) = 1.068, p = .347, respectively. Likewise, ANOVA failed
to detect a significant strain x sex, strain x drug treatment, sex x drug treatment, or strain
x sex x drug treatment interaction: F (1, 123) = .261, p = .611; F (2, 123) = .292, p =
.747; F (2, 123) = 1.152, p = .320; and F (2, 123) = 1.158, p = .318; respectively. (See
Table 8 for data.)

Table 8. Mean latency (s) to display a pain response in the hotplate algesia test in
Experiment 2 by strain, sex, and drug treatment
B6
Drug Treatment Male
Saline
15.28 (1.58)
10 mg/kg
12.29 (1.37)
30 mg/kg
14.36 (1.37)

Female
15.50 (1.43)
14.70 (1.43)
15.78 (1.37)

D2
Male
17.67 (1.37)
16.54 (1.43)
19.08 (1.43)

Female
19.73 (1.50)
18.75 (1.37)
16.36 (1.37)

Numbers in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J.
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Light-Dark
Although all animals were tested in the light/ dark apparatus, a computer file was
lost resulting in data being lost for four B6 males: two received saline, one treated with
10 mg/kg SNRIX, and 1 treated with 30 mg/kg SNRIX. To determine the nature of the
missing data, we examined the correlations of the missing data with all other variables
examined in the experiment. The largest correlation was with activity in the EZM, r =
.229, p = .039. Considering that the significant correlations found were relatively weak,
the decision was made to proceed with the analysis despite the data not being missing at
random.
Percentage of time spent in the light. ANOVA revealed a main effect of strain,
F (1, 119) = 54.108, p < .001, with B6 mice spending a greater percentage of time in the
light side of the apparatus. Additionally, a main effect of sex was found, F (1, 119) =
18.595, p < .001, with males spending more time in the light than females. ANOVA
failed to detect a significant main effect of drug treatment, F (2, 119) = 1.223, p = .298.
However a significant strain x sex interaction was found, F (1, 119) = 4.678, p = .033.
Analysis of simple effects revealed that B6 males and females did not differ while D2
males spent more time in the light half of the apparatus than did D2 females. Further, B6
males spent more time in the light than D2 males, and, likewise, B6 females spent more
time in the light than did D2 females. ANOVA failed to detect a significant strain x drug
treatment interaction, F (2, 119) = .831, p = .438. ANOVA failed to detect a significant
sex x drug treatment interaction despite a trend towards significance, F (2, 119) = 2.855,
p = .061. Likewise, although not significant, ANOVA revealed a trend towards a
significant strain x sex x drug treatment interaction, F (2, 119) = 2.798, p = .065. See
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Figure 3. Further inspection suggested that 10 and 30 mg/kg SNRIX resulted in B6 males
spending a decreased amount of time in the light side of the apparatus as compared to
saline treated B6 males while neither dose had an effect on any other strain and sex
combination as compared to their respective control. Further, of those animals in the
saline condition, B6 males spent the greatest percentage of time in the light followed by
B6 females and D2 males, which did not differ, and then D2 females. B6 males, B6
females, and D2 males administered 10 mg/kg SNRIX did not differ whereas D2 females
administered the same dose spent less time in the light than all three. Likewise, the same
pattern of response was seen for those animals treated with 30 mg/kg SNRIX.

Figure 3. The effect of SNRIX on percentage of time spent in the light side of the lightdark apparatus by drug, sex, and dosage. Data are presented as means ± SEM. The strain
by sex by drug treatment interaction did not quite reach significance (F (2, 119) = 2.798,
p = .065, ES: f = .217). B6 = C57BL/6J, D2 = DBA/2J.
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Total distance traveled in the light/ dark apparatus. ANOVA revealed a
significant main effect of strain, F (1, 119) = 4.718, p = .032, with B6 mice traveling a
greater distance than D2 mice. However, the main effects of sex and drug treatment were
not found to be significant, F (1, 119) = 1.911, p = .17, and F (2, 119) = .188, p = .83,
respectively. ANOVA did find a significant strain x sex interaction, F (1, 119) = 19.280,
p < .001. Analysis of simple effects revealed that male B6 and D2 animals did not differ,
but female B6 animals traveled a greater distance than female D2 animals. When
comparing male and female B6 mice, it was found that females traveled further than
males. On the other hand, male D2 mice traveled further than female D2 mice. No other
significant interactions were found: strain x drug treatment, F (2, 119) = .236, p = .79;
sex x drug treatment, F (2, 119) = 1.245, p = .292; and strain x sex x drug treatment, F (2,
119) = .669, p = .52. (See Table 9 for data.)
Percentage of total distance traveled occurring in the light side of the
apparatus. ANOVA revealed a significant main effect of strain, F (1, 119) = 144.405, p
< .001, with the percentage of distance traveled occurring in the light by B6 mice being
greater than that of D2 mice. A significant main effect of sex was also found, F (1, 119) =
12.714, p = .001, with the percentage of total distance traveled in the light being greater
for males than females. ANOVA failed to detect a main effect of drug treatment, F (2,
119) = .004, p = .996. Likewise, ANOVA did not detect significant, strain x sex, strain x
drug treatment, sex x drug treatment, or strain x sex x drug treatment interactions: F (1,
119) = .845, p = .36; F (2, 119) = .857, p = .427; F (2, 119) = 1.619, p = .203; and F (2,
119) = 1.721, p = .183; respectively. (See Table 9 for data.)
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Table 9. Mean distance (cm) traveled and mean percentage of that distance traveled
occurring in the light side of the light-dark apparatus by strain, sex, and drug
treatment in Experiment 2
B6
Drug Treatment Male
Female
Total Distance Traveled
Saline
1006.9 (93.0)
1142.6 (74.2)
10 mg/kg
1008.4 (74.2)
1097.8 (74.2)
30 mg/kg
990.6 (74.2)
1157.6 (71.1)

Saline
10 mg/kg
30 mg/kg

D2
Male

Female

1191.3 (71.1)
1116.7 (74.2)
987.1 (74.2)

813.7 (77.8)
839.4 (71.1)
889.4 (71.1)

Percentage of Total Distance Occurring in Light
40.26 (2.30)
32.13 (1.84)
23.40 (1.76)
35.06 (1.84)
33.99 (1.84)
25.93 (1.84)
34.26 (1.84)
34.91 (1.76)
24.46 (1.84)

19.05 (1.93)
19.38 (1.76)
20.90 (1.76)

Numbers in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J.

Acoustic Startle/ Prepulse Inhibition
Response to 120 db startle stimulus. ANOVA revealed a significant main effect
of strain, F (1, 123) = 156.750, p < .001, with B6 mice displaying a greater response than
D2 mice. A significant main effect of sex was found as well, F (1, 123) = 14.926, p <
.001, with males responding more forcefully than females. ANOVA failed to detect a
significant main effect of drug treatment, F (2, 123) = .232, p = .794. A significant strain
x sex interaction was found, F (1, 123) = 6.883, p = .01. Analysis of simple effects
revealed that B6 males displayed a greater startle response than did B6 females, but D2
males and females did not differ. Additionally, the response of B6 males was greater than
D2 males, and B6 females displayed a greater response than D2 females. ANOVA failed
to detect significant strain x drug treatment, sex x drug treatment, or strain x sex x drug
treatment interactions: F (2, 123) = .545, p = .581; F (2, 123) = .031, p = .969; and F (2,
123) = .001, p = .999; respectively.
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Percentage of prepulse inhibition of the startle response at 70 db. ANOVA
revealed a significant main effect of strain, F (1, 123) = 49.846, p < .001, with B6 mice
displaying a greater degree of inhibition than D2 mice. ANOVA failed to detect a
significant main effect of sex, F (1, 123) = .810, p = .37. There was a non-significant
trend towards an effect of drug treatment, F (2, 123) = 2.832, p = .063, see Figure 4.
Further inspection showed that while 10 mg/kg SNRIX was no different than SAL,
animals administered 30 mg/kg SNRIX displayed a greater degree of inhibition than did
those administered SAL. No significant interactions were found: strain x sex, F (1, 123) =
1.780, p = .185; strain x drug treatment, F (2, 123) = .142, p = .867; sex x drug treatment,
F (2, 123) = .013, p = .849; or strain x sex x drug treatment, F (2, 123) = .823, p = .442.
Percentage of prepulse inhibition of the startle response at 80 db. ANOVA
revealed a significant main effect of strain, F (1, 123) = 158.469, p < .001, with B6 mice
displaying a greater degree of inhibition than D2 mice. A significant main effect of sex
was also found, F (1, 123) = 9.426, p = .003, with males showing more inhibition than
females. Additionally, ANOVA revealed a significant main effect of drug treatment, F (2,
123) = 4.291, p = .016. See Figure 4. Post hoc analysis indicated that animals
administered 10 mg/kg SNRIX did not differ from control animals. However, animals
treated with 30 mg/kg SNRIX displayed a greater degree of inhibition than either those
treated with 10 mg/kg SNRIX or saline. ANOVA failed to detect significant strain x sex,
strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment interactions:
F (1, 123) = 2.143, p = .146; F (2, 123) = 1.929, p = .150; F (2, 123) = .820, p = .443; and
F (2, 123) = 1.652, p = .196; respectively .
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Figure 4. The effect of SNRIX on startle response and prepulse inhibition of the startle response. Data are presented as means ± SEM.
SNRIX had no effect on the startle response to a 120 db white noise burst. 30 mg/kg, but not 10 mg/kg SNRIX increased inhibition of
the startle response with the 80 db prepulse (* = p < .02 compared to saline). A similar effect was seen with the 75 db prepulse, but
this did not quite reach significance (F (2, 123) = 2.832, p = .063, ES: f = .215) SNRIX had no effect on prepulse inhibition at 85 db.
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Percentage of prepulse inhibition of the startle response at 85 db. ANOVA
detected a significant main effect of strain, F (1, 123) = 113.078, p < .001, with B6 mice
displaying a greater degree of inhibition than D2 mice. ANOVA failed to detect
significant main effects of sex or drug treatment: F (1, 123) = 2.869, p = .093, and F (2,
123) = 1.492, p = .229, respectively. Likewise, ANOVA failed to detect significant strain
x sex, strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment
interactions: F (1, 123) = .469, p = .495; F (2, 123) = 2.369, p = .098; F (2, 123) = .448, p
= .64; and F (2, 123) = .034, p = .967; respectively.
Fear Conditioning
Training: Baseline activity. ANOVA revealed a significant main effect of strain,
F (1, 123) = 163.795, p < .001, with B6 mice being more active than D2 mice. ANOVA
failed to detect significant main effects of sex or drug treatment: F (1, 123) = .722, p =
.397, and F (2, 123) = .047, p = .954, respectively. ANOVA did uncover a significant
strain x sex interaction, F (1, 123) = 5.614, p = .019. Analysis of simple effects revealed
that B6 females were more active than B6 males, but D2 males and females did not
differ. Further, B6 males were more active than D2 males, and B6 females were more
active than D2 females. ANOVA failed to detect significant strain x drug treatment, sex x
drug treatment, or strain x sex x drug treatment interactions: F (2, 123) = .009, p = .991;
F (2, 123) = .651, p = .523; and F (2, 123) = .061, p = .941; respectively.
Suppression of activity by training. ANOVA revealed a non-significant trend
towards an effect of strain, F (1, 123) = 3.706, p = .057, with B6 mice showing a greater
suppression of activity than D2 mice. No other effects approached significance: sex, F (1,
123) = .981, p = .324; drug treatment, F (2, 123) = .748, p = .476; strain x sex, F (1, 123)
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= .900, p = .345; strain x drug treatment, F (2, 123) = 1.760, p = .176; sex x drug
treatment, F (2, 123) = 1.021, p = .363; and strain x sex x drug treatment, F (2, 123) =
.314, p = .731. (See Table 10 for data.)

Table 10. Means and standard errors of fear conditioning measures in Experiment 2
by strain, age, and sex
B6
Drug Treatment Male
Female
Suppression of Activity by Training
Saline
.336 (.125)
.282 (.113)
10 mg/kg
.311 (.108)
.304 (.113)
30 mg/kg
.228 (.108)
.297 (.108)

D2
Male

Female

.344 (.108)
.325 (.113)
.395 (.113)

.407 (.118)
.321 (.108)
.712 (.108)

Saline
10 mg/kg
30 mg/kg

Suppression of Activity by Training Context
.336 (.060)
.323 (.054)
.702 (.052)
.313 (.052)
.361 (.054)
.795 (.054)
.352 (.052)
.347 (.052)
.707 (.054)

.633 (.057)
.543 (.052)
.645 (.052)

Saline
10 mg/kg
30 mg/kg

Suppression of Activity by Cue
.238 (.050)
.192 (.045)
.220 (.043)
.190 (.045)
.222 (.043)
.153 (.043)

.223 (.047)
.288 (.043)
.269 (.043)

.258 (.043)
.342 (.045)
.217 (.045)

Numbers are means, and numbers in parentheses are standard errors. Suppression of
activity by training is calculated as beam breaks during the 30 seconds following the final
tone-shock pairing divided by the average number of beam breaks per 30 second bin
during the first two minutes of the training session. Suppression of activity by the training
context is calculated as the average number of beam breaks per 30 second bin during
exposure to the training context on the second day divided by the average number of
beam breaks per 30 second bin during the first two minutes of the training session.
Suppression of activity by the cue is calculated as the average number of beam breaks per
30 second bin during the first three minutes of exposure to the altered context on the
second day divided by the average number of beam breaks per 30 second bin during the
presentation of the tone in the altered context. (Smaller numbers indicate a greater
suppression of activity.) B6 = C57Bl/6J, D2 = DBA/2J
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Contextual conditioning: Suppression of baseline activity by training context.
ANOVA detected a significant main effect of strain, F (1, 123) = 114.865, p < .001, with
B6 mice displaying less activity in the training context than D2 mice relative to their
baseline activity during training. ANOVA failed to detect main effects of sex or drug
treatment: F (1, 123) = 3.598, p = .06, and F (2, 123) = .070, p = .933, respectively.
However, ANOVA revealed a significant strain x sex interaction, F (1, 123) = 4.929, p =
.028. Analysis of simple effects revealed that B6 males and females did not differ, but D2
males displayed a lesser suppression of activity in response to the training context than
did D2 females. Further, D2 mice of both sexes were more active during exposure to the
training context as compared to their baseline activity than B6 mice of the respective sex.
ANOVA failed to detect significant strain x drug treatment, sex x drug treatment, or
strain x sex x drug treatment interactions: F (2, 123) = .012, p = .988; F (2, 123) = .504, p
= .605; and F (2, 123) = 1.746, p = .179, respectively. (See Table 10 for data.)
Cued conditioning: Activity in the altered context. ANOVA failed to detect a
significant main effect of strain, F (1, 123) = 2.091, p = .151. However, a significant
main effect of sex was found, F (1, 123) = 3.993, p = .048, with females showing a lower
level of activity in the altered context than males. ANOVA failed to detect a significant
effect of drug treatment, F (2, 123) = .758, p = .471. The strain x sex interaction was
significant, F (1, 123) = 6.690, p = .011. Analysis of simple effects revealed that B6
males and females did not differ, but D2 females were less active than D2 males.
Additionally, B6 and D2 males did not differ, but D2 females were less active than B6
females. ANOVA failed to detect significant strain x drug treatment, sex x drug
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treatment, or strain x sex x drug treatment interactions: F (2, 123) = .422, p = .657; F (2,
123) = .484, p = .618; and F (2, 123) = 1.487, p = .230, respectively.
Cue suppression of activity in the altered context. ANOVA revealed a significant
main effect of strain, F (1, 123) = 6.093, p = .015, with B6 mice displaying a greater
reduction in activity during the presentation of the tone than D2 mice. ANOVA failed to
detect significant main effects of sex or drug treatment: F (1, 123) = 1.385, p = .242, and
F (2, 123) = 1.092, p = .339, respectively. Likewise, ANOVA failed to detect significant
strain x sex, strain x drug treatment, sex x drug treatment, or strain x sex x drug treatment
interactions: F (1, 123) = .488, p = .486; F (2, 123) = .917, p = .402; F (2, 123) = .193, p
= .825; and F (2, 123) = .750, p = .475; respectively. (See Table 10 for data.)
Tail Suspension
All animals were tested on tail suspension, but data from 10 mice were lost due to
a computer error. Of those animals seven were B6 (3 males receiving 10 mg/kg SNRIX,
1 female receiving saline, 1 female receiving 10 mg/kg SNRIX, and 2 females receiving
30 mg/kg SNRIX) and three were D2 (1 male receiving 10 mg/kg SNRIX and 2 females
receiving 30 mg/kg SNRIX). We examined the correlations of the missing data with all
other variables included in the experiment to determine if the data was missing at
random. The missing data was significantly correlated with three variables: activity
during the final 30 s of training for fear conditioning, r = .230, p = .007; activity in the
altered context of fear conditioning, r = .205, p = .017; and tail climbing during tail
suspension testing, r = - .180, p = .036. Although the data can not be said to be missing at
random, the correlations are relatively small, and the analysis was carried out on
available data.
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Tail climbing. We observed a large number of animals that climbed their tails
during the tail suspension procedure, 31.2 %. Data for tail climbing was recorded (coded
dichotomously) in the experimenter‟s notes, and therefore no data was lost for this
variable. Logistic regression analysis indicated that strain did not predict tail climbing,
OR: .701, p = .375, 95% CI: .320 – 1.536. However, sex did predict tail climbing, OR:
3.766, p = .001, 95% CI: 1.668 – 8.500, with males being over three times more likely to
climb their tails than females. Drug treatment was not associated with tail climbing, p =
.586 (10 mg/kg SNRIX versus SAL: OR: 1.104, p =.837, 95% CI: .429 – 2.838; 30 mg/kg
SNRIX versus SAL: OR: .680, p = .442, 95% CI: .255 – 1.818). Animals that climbed
their tail were omitted from further analysis of tail suspension data.
Time below threshold (immobility): Time below threshold per 30 s block of the
six minute session. The six minute session was divided into 30 s intervals and analyzed
via a repeated measures ANOVA using interval as a within subjects variable. Repeated
measures ANOVA revealed a significant effect of interval, F (11, 814) = 66.132, p <
.001. Further, inspection of the data showed that time spent below threshold did not
change during the first two intervals. Immobility increased between the third and eighth
interval at which point it reached a plateau. Repeated measures ANOVA revealed a
significant interval by strain interaction, F (11, 814) = 8.466, p < .001. Inspection of the
data showed that B6 mice initially exhibited less immobility than D2 mice. However, B6
mice demonstrated increasing immobility at a rate greater than D2 mice resulting in B6
mice reaching a greater level of immobility than D2 mice from interval six through ten.
B6 and D2 mice did not differ between intervals 10 and 12. Repeated measures ANOVA
failed to detect any further significant interactions: interval x sex, F (11, 814) = .986, p =
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.457; interval x drug treatment, F (22, 814) = .953, p = .524; interval x strain x sex, F
(11, 814) = .597, p = .832; interval x strain x drug treatment, F (22, 814) = .876, p = .627;
interval x sex x drug treatment, F (22, 814) = .975, p = .495; or interval x strain x sex x
drug treatment, F (22, 814) = 1.036, p = .416.
Overall time below threshold. ANOVA failed to detect a significant main effect
of strain, F (1, 74) = 2.729, p = .103. A significant main effect of sex was found, F (1,
74) = 4.089, p = .047, with females spending a greater amount of time immobile than
males. ANOVA failed to detect a significant main effect of drug treatment, F (2, 74) =
.361, p = .698. Likewise, ANOVA failed to detect significant strain x sex, strain x drug
treatment, sex x drug treatment, or strain x sex x drug treatment interactions: F (1, 74) =
.164, p = .687; F (2, 74) = 1.143, p = .324, F (2, 74) = .648, p = .526; and F (2, 74) =
.615, p = .544; respectively. (See Table 11 for data.)

Table 11. Mean time (s) spent below threshold (immobility) during the tail
suspension test in Experiment 2 by strain, sex, and drug treatment
B6
Drug Treatment Male
Saline
177.00 (23.45)
10 mg/kg
209.00 (23.45)
30 mg/kg
159.17 (19.15)

Female
210.56 (15.64)
192.10 (14.83)
194.00 (14.83)

D2
Male
152.00 (17.73)
162.80 (20.98)
164.89 (15.64)

Female
172.38 (16.58)
188.57 (17.73)
196.00 (17.73)

Animals that climbed their tails were not included in the analysis. Numbers in
parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J.
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Experiment 3
Elevated Zero Maze
Activity in the closed quadrants. ANOVA found a significant effect of strain, F
(1, 54) = 18.004, p < .001, with B6 mice being more active than D2 mice. Likewise, the
effect of age was significant, F (1, 54) = 3.287, p = .045. (See Figure 5.) 6wk mice were
the most active followed by 8wk and 4wk mice. Post hoc testing showed that the 8wk
mice were the same as 4wk or 6wk, but the 6wk mice were more active than their 4wk
counterparts. The strain by age interaction failed to reach significance, F (2, 54) = .763, p
= .471. (Data are presented in Table 12.)
Latency to enter an open quadrant. ANOVA indicated a significant effect of
strain, F (1, 54) = 12.849, p = .001, with D2 mice showing a longer latency than B6 mice.
However, there was no effect of age, F (2, 54) = 1.903, p = .159, and the strain by age
interaction was non-significant, F (2, 54) = .459, p = .634. (Data are presented in Table
12.)
Percentage of time spent in an open quadrant. ANOVA revealed a significant
effect of strain, F (1, 54) = 7.067, p = .01, with B6 mice spending more time in the open
than D2 mice. There was a trend towards a main effect of age, but this did not quite reach
significance, F (2, 54) = 2.971, p = .060. (See Figure 5.) 8wk mice spent the least amount
of time in the open followed by 4wk and 6wk mice, which spent the greatest amount of
time in the open. The strain by age interaction was found to be non-significant, F (2, 54)
= .975, p = .384. (Data are presented in Table 12.)
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Figure 5. Age-related differences in behavior in the elevated zero maze. Data are
presented as Means ± SEM A.) Activity in the closed quadrants of the maze. Activity is
measured as beam breaks per second spent in the closed quadrants. Groups that do not
share a common lowercase letter are different at the level, p < .05. B.) Percentage of time
spent in the open quadrants of the maze. The main effect of age did not quite reach
significance (F (2, 54) = 2.971, p = .060, ES: f = .331). 4 wk = four weeks of age, 6 wk =
six weeks of age, 8 wk = eight weeks of age.
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Table 12. Means and standard errors of measures in the elevated zero maze by age
and strain

Strain
B6
D2

4 weeks
6 weeks
Percentage of Time in the Open Quadrants
23.28 (3.29)
27.23 (3.29)
17.23 (3.29)
24.03 (3.29)

8 weeks

B6
D2

Activity in the Closed Quadrants
2.49 (.11)
2.63 (.11)
1.97 (.11)
2.40 (.11)

2.55 (.11)
2.14 (.11)

B6
D2

Latency (s) to Enter an Open Quadrant
4.09 (3.22)
5.89 (3.22)
10.52 (3.22)
15.15 (3.22)

7.29 (3.22)
19.89 (3.22)

23.88 (3.29)
11.68 (3.29)

Numbers are means, and numbers in parentheses are standard errors. Activity is measured
as beam breaks per second in the closed quadrants. B6 = C57Bl/6J, D2 = DBA/2J.

Open Field
Total distance traveled. ANOVA revealed a significant effect of strain on the
distance traveled in the open field, F (1, 54) = 22.701, p < .001, with B6 mice traveling
further than D2 mice. The main effect of age and the strain by age interaction failed to
reach significance, F (2, 54) = .497, p = .611, and F (2, 54) = 1.813, p = .173,
respectively. (Data are presented in Figure 6.)
Rears. ANOVA found no effects of the independent variables on the number of
rears in the open field: strain, F (1, 54) = .019, p = .892; age, F (2, 54) = .144, p = .866;
and strain by age, F (2, 54) = 1.501, p = .232. (Data are presented in Table 13.)
Habituation Ratio. ANOVA indicated that the independent variables were
without effect on the habituation to the open field: strain, F (1, 54) = .671, p = .416; age,
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F (2, 54) = 1.538, p = .224; and strain by age, F (2, 54) = 2.014, p = .143. (Data are
presented in Table 13.)
Percentage of time spent in the corners of the arena. ANOVA revealed a
significant effect of strain on time spent in the corners, F (1, 54) = 47.051, p < .001, with
B6 mice spending more time in the corners than D2 mice. However, there was no effect
of age, F (2, 54) = .909, p = .409, and the strain by age interaction was not significant, F
(2, 54) = .143, p = .867. (Data are presented in Table 13.)

Table 13. Means and standard errors of number of rears, habituation ratio, and
percentage of time spent in the corners of the open field by age and strain

Strain
B6
D2

4 weeks
Rears
128.2 (15.53)
157.1 (15.53)

6 weeks

8 weeks

141.2 (15.53)
142.4 (15.53)

147.5 (15.53)
122.6 (15.53)

B6
D2

Habituation Ratio
.378 (.036)
.486 (.036)

.403 (.036)
.382 (.036)

.377 (.036)
.362 (.036)

B6
D2

Percentage of Time Spent in Corners of the Arena
45.99 (2.08)
44.00 (2.08)
43.51 (2.08)
34.06 (2.08)
33.60 (2.08)
30.96 (2.08)

Numbers are means, and numbers in parentheses are standard errors. Habituation ratio is
the distance traveled during the last five minutes of testing over the sum of the distance
traveled during the first and last five minutes of testing. B6 = C57Bl/6J, D2 = DBA/2J.

Percentage time spent in the center of the arena. ANOVA found a significant
effect of strain, F (1, 54) = 74.792, p < .001, with B6 mice spending more time in the
center of the arena than D2 mice. The effect of age did not reach significance, F (2, 54) =
1.223, p = .302, but there was a significant strain by age interaction, F (2, 54) = 5.625, p
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= .006. (See Figure 6.) Analysis of simple effects showed that at all ages B6 mice spent
more time in the center than D2 mice. Among B6 mice, 4wk and 6wk did not differ, but
8wk mice spent more time in the center than either of the younger age groups. On the
other hand, there was no difference between the age groups for D2 mice.
Percentage of total distance traveled occurring in the center of the arena.
ANOVA revealed a significant main effect of strain, F (1, 54) = 49.635, p < .001, with
B6 mice traveling a greater distance in the center of the arena than D2 mice. The effect of
age failed to reach significance, F (2, 54) = .114, p = .893, but there was a significant
strain by age interaction, F (2, 54) = 3.729, p = .030. (See Figure 6.) Analysis of simple
effects was not able to detect any differences by age for either strain, but confirmed that
at all ages B6 mice traveled a greater distance than D2 mice.
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Figure 6. Effect of age and strain on measures in the open field. Data are presented as
means ± SEM. A.) Total distance traveled (cm). The strain by age interaction was not
significant and is presented only for the purpose of comparison. B.) The percentage of the
total distance traveled that occurred in the center of the open field. C.) Percentage of time
spent in the center of the open field. Groups that do not share a common lowercase letter
are different at the level, p < .05. 4 wk = four weeks of age, 6 wk = six weeks of age, 8
wk = eight weeks of age, B6 = C57Bl/6J, D2 = DBA/2J.
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Hotplate
Latency to display hindpaw pain response. ANOVA did not find any effects of
the independent variables on latency to display a pain response: strain, F (1, 54) = .005, p
= .944; age, F (2, 54) = .011, p = .989; strain by age, F (2, 54) = 1.164, p = .320. (Data
are presented in Table 14.)

Table 14. Mean latency (s) to display a pain response in the hotplate algesia test by
age and strain
Strain
B6
D2

4 weeks
17.75 (2.16)
16.16 (2.16)

6 weeks
17.65 (2.16)
15.70 (2.16)

8 weeks
14.70 (2.16)
18.63 (2.16)

Numbers in parentheses are standard errors. B6 = C57Bl/6J, D2 = DBA/2J.

Light-Dark
Percentage of time spent in the light. ANOVA revealed a significant effect of
strain, F (1, 54) = 13.688, p = .001, with B6 mice spending more time in the light side of
the apparatus. However, the effect of age and the strain by age interaction were not
significant, F (2, 54) = 1.852, p = .167, and F (2, 54) = 1.435, p = .247, respectively.
(Data are presented in table 15.)
Total distance traveled in the light-dark apparatus. ANOVA showed that
there was a significant effect of strain, F (1, 54) = 7.267, p = .009, with B6 mice traveling
a greater distance than D2 mice. The effect of age and the age by strain interaction were
not significant, F (2, 54) = 1.254, p = .294, and F (2, 54) = 1.705, p = .191, respectively.
(Data are presented in table 15.)
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Table 15. Means and standard errors of measures in the light-dark apparatus by
age and strain

Strain
B6
D2

4 weeks
6 weeks
Percentage of Time Spent in the Light Side
39.86 (2.69)
37.15 (2.69)
32.15 (2.69)
33.35 (2.69)

8 weeks

B6
D2

Distance (cm) Traveled
1066.2 (76.45)
1057.7 (76.45)
1044.2 (76.45)
878.6 (76.45)

B6
D2

Percentage of Distance Traveled in the Light Side
42.49 (1.9)
37.77 (1.9)
39.34 (1.9)
31.35 (1.9)
27.61 (1.9)
22.88 (1.9)

37.63 (2.69)
24.73 (2.69)

1236.4 (76.45)
932.7 (76.45)

Numbers are means, and numbers in parentheses are standard errors. B6 = C57Bl/6J, D2
= DBA/2J.

Percentage of total distance traveled occurring in the light side of the
apparatus. ANOVA found a significant effect of strain, F (1, 54) = 65.754, p < .001,
with B6 mice traveling a greater distance in the light than D2 mice. Likewise, the effect
of age was significant, F (2, 54) = 5.001, p = .010. (See Figure 7.) Post hoc testing
indicated that 6wk mice, which traveled an intermediate distance in the light, did not
differ from those 8wk or 4wk. On the other hand, the 4wk mice traveled a greater
distance in the light than did the 8wk mice. ANOVA indicated that the stain by age
interaction was not significant, F (2, 54) = 1.593, p = .213. (Data are presented in table
15.)
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Figure 7. Age-related differences in measures in the light-dark apparatus. Data are
presented as means ± SEM. A.) Total distance traveled in the light-dark apparatus. The
effect of age was not significant and is presented for the purpose of comparison. B.)
Percentage of the total distance traveled occurring in the light side of the apparatus.
Groups that do not share a common letter are different at the level, p < .05. C.)
Percentage of time spent in the light side of the apparatus. The effect of age was not
significant and is presented for the purpose of comparison. 4 wk = four weeks of age, 6
wk = six weeks of age, 8 wk = eight weeks of age.
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Fear Conditioning
Training: Baseline activity. ANOVA found a significant effect of strain on
baseline activity, F (1, 54) = 34.488, p < .001, with B6 mice being more active than D2
mice. However, the main effect of age and the strain by age interaction were not
significant, F (2, 54) = .205, p = .815, and F (2, 54) = .916, p = .406, respectively.
Suppression of activity by training. ANOVA did not find the independent variables to
have an effect on the suppression of activity by training: strain, F (1, 54) = .236, p = .629;
age, F (2, 54) = .447, p = .642; and age by strain, F (2, 54) = 1.012, p = .370. However,
the data did indicate that the training was successful with all animals displaying a
reduction in activity following the final shock-tone pairing (M = .378, SEM = .035).
Contextual conditioning: Suppression of baseline activity by training context.
ANOVA indicated that B6 mice showed a greater reduction of activity upon exposure to
the training context the following day than did D2 mice, F (1, 54) = 14.400, p < .001.
However, the main effect of age and the strain by age interaction were not significant, F
(1, 54) = .540, p = .586, and F (2, 54) = .906, p = .410, respectively.
Cued conditioning: Activity in the altered context. ANOVA found that B6 mice
were more active at baseline in the altered context than D2 mice, F (1, 54) = 7.245, p =
.009, but there was no effect of age, F (2, 54) = .227, p = .798. Likewise, the strain by age
interaction was not significant, F (2, 54) = .180, p = .836. Cue suppression of activity in
the altered context. ANOVA revealed that D2 mice showed a greater suppression of
activity in the altered context in response to the tone than did B6 mice, F (1, 54) =
20.869, p < .001. However, the main effect of age and the strain by age interaction were
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not significant, F (2, 54) = 2.055, p = .138, and F (2, 54) = .425, p = .656, respectively.
(Data are presented in Table 16.)

Table 16. Means and standard errors of fear conditioning measures by age and
strain.

Strain
B6
D2

4 weeks
6 weeks
Suppression of Activity by Training
.44 (.09)
.41 (.09)
.39 (.09)
.26 (.09)

8 weeks

B6
D2

Suppression of Activity by Training Context
.55 (.07)
.56 (.07)
.43 (.07)
.74 (.07)
.67 (.07)
.73 (.07)

B6
D2

Suppression of Activity by Cue
.38 (.05)
.30 (.05)
.14 (.05)
.14 (.05)

.34 (.09)
.43 (.09)

.40 (.05)
.24 (.05)

Numbers are means, and numbers in parentheses are standard errors. Suppression of
activity by training is calculated as beam breaks during the 30 seconds following the final
tone-shock pairing divided by the average number of beam breaks per 30 second bin
during the first two minutes of the training session. Suppression of activity by the training
context is calculated as the average number of beam breaks per 30 second bin during
exposure to the training context on the second day divided by the average number of
beam breaks per 30 second bin during the first two minutes of the training session.
Suppression of activity by the cue is calculated as the average number of beam breaks per
30 second bin during the first three minutes of exposure to the altered context on the
second day divided by the average number of beam breaks per 30 second bin during the
presentation of the tone in the altered context. (Smaller numbers indicate a greater
suppression of activity.) B6 = C57Bl/6J, D2 = DBA/2J.
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Tail Suspension
Three animals fell off the tail suspension apparatus during testing (one mouse
from each of the following groups: B6, 6wk; D2, 4wk; and D2 6wk). These animals were
therefore not included in the analysis. We did not observe any animals that climbed their
tails.
Time below threshold (immobility): Time below threshold per 30 s block of the
six minute session. Repeated measures ANOVA indicated that the within-subjects
variable, interval, was significant, F (11, 561) = 58.144, p < .001, with immobility
increasing from interval 2 – 8 and then reaching a plateau from interval 8- 12. Likewise,
the interval by strain interaction was significant, F (11, 561) = 12.403, p < .001, but the
interval by age interaction was not significant, F (22, 561) = 1.464, p = .080. The threeway interaction, interval by strain by age, was found to be significant, F (22, 561) =
1.603, p = .041. (See Figure 8.) The B6 mice exhibited a low level of immobility during
the first two intervals of testing followed by a sharp increase in immobility between
intervals two and four. The sharp increase was followed by a plateau in immobility from
intervals four through eight. On the other hand, D2 mice displayed higher initial levels of
immobility, which shifted more gradually during testing as compared to the B6 mice. At
individual 30 s blocks, there were very few differences by age within strains, but there
were multiple differences between strains and ages. (See Figure 8.)
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Figure 8. Time spent below threshold (immobility) in the tail suspension test by strain, age, and 30 second interval. Data are presented
as means ± SEM. The following groups were different at the level, p < .05: Interval 1: D2 4wk > all, D2 6wk, 8wk > B6 6wk, 8wk;
Interval 2: D2 4wk > all; Interval 4: B6 4wk > D2 6wk, B6 8wk > D2 6wk, 8wk; Interval 5: B6 all > D2 8wk; Interval 6: B6 6wk >
D2 8wk, B6 8wk > D2 6wk, 8wk; Interval 7: D2 4wk > D2 8wk, B6 8wk > D2 8wk; Interval 9: B6 6wk > B6 8wk, B6 6wk > D2
6wk; Interval 10: B6 6wk > D2 8wk, D2 4wk, 6wk > D2 8wk; Interval 11: B6 4wk > B6 6wk, B6 4wk > D2 6wk, 8wk, D2 4wk > D2
8wk; Interval 12: D2 4wk > B6 4wk, D2 4wk > D2 6wk, 8wk. 4 wk = four weeks of age, 6 wk = six weeks of age, 8 wk = eight weeks
of age, B6 = C57Bl/6J, D2 = DBA/2J.
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Overall time below threshold. ANOVA did not find an effect of strain on the total
time spent immobile during the tail suspension test, F (1, 51) = .647, p = .425. However,
there was a significant effect of age, F (2, 51) = 6.845, p = .002. Post hoc testing
indicated that 4wk mice spent more time immobile than 6wk or 8wk mice, but the 6wk
and 8wk mice did not differ. ANOVA also revealed a significant strain by age
interaction, F (2, 51) = 4.947, p = .011. (See Figure 9.) Analysis of simple effects showed
that there were no differences among B6 mice based on age. On the other hand 4wk D2
mice spent more time immobile than did their 6wk and 8wk counterparts, who did not
differ. Comparing the two strains, B6 and D2 mice did not differ at 4wk or 6wk, but 8wk
B6 mice spent more time immobile than did D2 mice of the same age.

Figure 9. Total time spent bellow threshold (immobility) during the tail suspension test
by strain and age. Data are presented as means ± SEM. Groups that do not share a
common lowercase letter are different at the level, p < .05. 4 wk = four weeks of age, 6
wk = six weeks of age, 8 wk = eight weeks of age, B6 = C57Bl/6J, D2 = DBA/2J.
62

Discussion and Conclusion
Discussion of Results of Experiment 1
Examining the effects of acute administration of CDZ on B6 and D2 mice in the
elevated zero maze, we found strain differences on all measures, which are similar to
those previously reported (Tarantino et al., 2000; Cook et al., 2001). On the other hand,
we did not find CDZ to affect activity or latency to enter an open quadrant. Previous
reports on the effects of CDZ on activity and latency in the EZM are variable, and a
number of authors do not include these measures at all. None the less, it seems that CDZ
generally increases or has no effect on activity and either decreases or is without effect on
latency (see Table 2). Increased latency is indicative of a heightened anxiety-like state;
thus, it is somewhat surprising that CDZ does not produce a consistent decrease in
latency. However, this measure has been previously noted as being quite variable and
difficult to interpret (Matto et al., 1997).
Considering the principle measure of anxiety-like behavior, time spent in the open
quadrants, we did see an effect of CDZ. Oddly, none of the doses tested differed from the
saline control, but 7.5 mg/kg of CDZ produced an axiolytic effect in comparison to
animals administered 2.5 or 5 mg/kg. While the drug by strain interaction was not
significant, visual inspection of the data suggest that the drug treatment effect was largely
due to CDZ having an anxiolytic effect in D2 mice but no effect in B6 mice. (See Figure
1.) This notion is supported when separate one-way ANOVAs were performed for each
strain. While the number of studies that have examined the effects of CDZ on mice in the
EZM is limited, most have found an anxiolytic effect (see Table 2). To our knowledge
the only other report on the effects of CDZ on B6 and D2 mice in the EZM is that of
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Mathiasen and colleagues (2008). They found CDZ to have no effect in D2 mice but an
axiogenic effect in B6 mice at a dose of 20 mg/kg. However, looking at their data overall,
it seems this may be an artifact of a sedative effect. Interestingly, when testing these
strains on the EPM, CDZ had no effect on B6 mice but an anxiolytic effect in D2 mice
(Mathiasen et al., 2008), which is similar to what we have found. Other studies of B6
mice in the EPM also indicate that CDZ is without effect on this strain (Rodgers et al.,
2002; Clément et al., 2009; Lalonde and Strazielle, 2010), but exceptions do exist
(Belzung et al., 2000; Paterson et al., 2010). Many authors have attributed this lack of
response to a floor effect as B6 mice generally exhibit a low level of anxiety-like
behavior, but there is evidence that the differential response to CDZ between B6 and D2
mice may be related to differences in GABAergic transmission (Hitzemann and
Hitzemann, 1999). Considering this, it would be helpful to examine the differences
between strains more thoroughly using receptor specific drugs and additional measures.
Interestingly, Rodgers and colleagues (2002) have additionally reported that
129S2/Sv mice are also unresponsive to the effects of CDZ in the EPM. This, with the
present findings and those of others, has major implications for the study of
benzodiazepines using transgenic mice as they are frequently produced using B6
blastocysts and 129 embryonic stem cells. While this highlights the importance of
considering strain effects in pharmacological research, it also suggests that expanded
pharmacological phenotyping of inbred strains could lead to a better understanding of the
genetics of GABAergic transmission and the treatment of anxiety disorders.
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Discussion of Results of Experiment 2
In order to characterize the effects of chronic administration of SNRIX in mice,
we administered SNRIX daily from PND 60 – 89. Beginning at PND 90 animals began a
four day battery of behavioral testing. Behavior was assayed using the following tests:
EZM, open field, hotplate algesia meter, light/ dark box, acoustic startle/ prepulse
inhibition, conditioned fear, and the tail suspension test. To determine if these effects
would vary according to strain and sex, male and female B6 and D2 mice were used. For
clarity of presentation, the results from each of these tests are discussed individually.
Body Weight
The body weight of both sexes and strains generally increased throughout the
course of the experiment, and differences were overall, generally small. Although some
differences were found to be statistically significant in the present study, the greatest
difference between means observed at the same time point (between B6 females and D2
males at PND 60) was only 5.02 g. Strain differences in body weight are often
inconsistent, for example some have found B6 mice to weigh more than D2 mice (Liu
and Gershenfeld, 2003), while others have found the opposite (Morris et al., 1999). More
interestingly, we did not find an effect of SNRIX on body weight. We are unaware of any
reports of the effects of SNRIX on body weight in mice. However, ten days treatment
with SNRIX in sham operated female bulbectomized rats decreased body weight
(Oliveira et al., 2004), but had no effect on body weight in male rats treated for 21 days
(Xu et al., 2003). Drugs acting on monoamine systems are known to affect appetite,
feeding behavior, and the regulation of body weight, and the effects of antidepressant
agents on weight gain appear to be complex (Gobshtis et al., 2007). Further, it is not clear
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to what degree the regulation of body weight is similar between clinical and preclinical
populations. However, our failure to find an effect of SNRIX on body weight
corresponds with reports that SNRIX does not affect weight gain in clinical populations
(Deshmukh and Franco, 2003). As the effects of antidepressant drugs on body weight can
exert considerable influence on patient compliance and are of particular concern for the
treatment of patients with comorbid obesity-related diseases (Deshmukh and Franco,
2003), further investigation would be worthwhile.
Elevated Zero Maze
Extending the pharmacological characterization of the EZM in mice was a
primary goal of this experiment. Therefore, mice were tested on this measure the first day
following SNRIX administration. Increases in the percentage of time spent in the open
quadrants of the elevated zero maze is considered to reflect an anxiolytic effect. We
found that B6 mice spent a greater percentage of time in the open quadrants than D2
mice, which concurs with previously reported findings (Cook et al., 2001). However, we
did not find a significant effect of SNRIX. Similarly, acute treatment with SNRIX has no
effect on behavior in the EZM in female NMRI mice (Troelsen et al., 2005).
Interestingly, Troelsen et al. (2005) found duloxetine, another SNRI, to have no effect in
mice on the EZM when administered acutely but to have an axiolytic effect after chronic
administration. There are numerous possibilities for the difference between the effects of
these two drugs, but duloxetine does have a greater affinity for the norepinephrine
transporter (NET) at lower doses compared to SNRIX (Troelsen et al., 2005). However,
further studies would be needed to determine what effect this might have. The EPM, from
which the EZM was derived, similarly has been shown to be generally insensitive to the
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effects of antidepressant drugs. Chronic administration of SNRIX in sham operated
female bulbectomized rats is without effect on behavior in the EPM (Oliveira et al.,
2004). Likewise, imipramine (Cole and Rodgers, 1995), desipramine (Gobshtis et al.,
2007), fluvoxamine (Rodgers et al., 1997), paroxetine (Goeldner et al., 2005), and
bupropion (Carrasco et al., 2004) have all been found to have no effect on mouse
behavior in the EPM. On the other hand, in mice, fluoxetine has been shown to have an
anxiogenic effect when administered chronically but an anxiolytic effect if administered
acutely (Goeldner et al., 2005), still yet others have found acute administration of
fluoxetine to be without effect (Holmes and Rodgers, 2003).
Similar to the percentage of time in the open, we did not find an effect of SNRIX
on activity or latency to enter an open quadrant in the EZM. Considering other
antidepressants, acute administration of desipramine (Gur et al., 2007), amitriptyline,
citatlopram, fluoxetine, paroxetine, and venlafaxine (Toelsen et al., 2005) are without an
effect on activity or latency in mice on the EZM. However, with duloxetine, Troelsen and
colleagues (2005) found acute, but not chronic, administration increased latency while
chronic, but not acute, treatment increased activity in female NMRI mice. Although we
did not find an effect of SNRIX on these measures, we did find a main effect of strain for
activity and a strain by sex interaction for latency. B6 mice were more active than D2
mice. With regards to latency, male B6 and D2 mice did not differ, while female D2 mice
displayed a greater latency than their B6 counterparts. While the relationships between
strains on these measures concur with those previously reported, the sex differences seem
less consistent (Cook et al., 2001).

67

Others have suggested that the EZM may be a useful test to detect delayed effects
of antidepressants (Troelsen et al., 2005). However, our data suggest that chronic SNRIX
is without effects on behavior in the EZM. Generally speaking, both the EZM and the
EPM have not demonstrated a robust ability to detect the effects of antidepressant agents,
with negative or conflicting results frequently being obtained (vide supra). Further, the
elevated plus maze has been shown to be highly sensitive to slight environmental
differences (Whalsten et al., 2003). These points and our finding suggest that elevated
maze tests of anxiety-like behavior are not a highly efficient method of investigating the
effects of antidepressant drugs and a larger number of animals may be needed to achieve
the power necessary to detect effects if they exist.
Open Field
We found a significant interaction between sex and strain and no effect of
treatment with SNRIX on the total distance traveled in the open field. D2 males and B6
mice of either sex did not differ, but all traveled more than D2 females. This is similar to
a previous report that B6 mice travel a greater distance than do D2 mice, however only
males were examined (Liu and Gershenfeld, 2003). Reports of the effects of SNRIX in
mice on this measure vary greatly with strain. In B6 mice an acute dose of 40 mg/kg
SNRIX, but not lower doses tested, increased distance traveled (Kos et al., 2006). On the
other hand, acute doses of SNRIX as low as 2.5 mg/kg in NMRI mice (Brocco et al.,
2002) and 16 mg/kg in swiss mice (Redrobe et al., 1998) increase distance traveled in the
open field. Still yet, using knockout mice maintained on a mixed B6 129SvEv
background, it has been reported that in the wild-type controls 20 mg/kg SNRIX
administered acutely was without effect but the same dose administered daily for 21 days
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produced a decrease in the distance traveled (Mitchell et al., 2006). Our failure to find an
effect of SNRIX in B6 mice may due to the highest dosage we tested, 30 mg/kg, being
too low to elicit an effect or possibly due to a difference between chronic and acute
treatment in this strain. Such variation between strains in the effects of SNRIX highlights
the importance of strain selection in pharmacological research, especially when
transgenic animal models are used.
We additionally found an interaction between sex and strain on the frequency of
rearing. B6 females and D2 males reared the most followed by B6 males and D2 females.
This finding is contrary to another that found B6 males to rear more frequently than D2
males, but females were not tested (Liu and Gershenfeld, 2003). We further found an
effect of sex on the habituation ratio, with males exhibiting a greater degree of
habituation to the open field than females, and an interaction between strain and sex on
the percentage of time spent in the corners of the arena. B6 males and females spent the
most time in the corners followed by D2 males and then D2 females. We did not find any
effects of SNRIX treatment on the frequency of rearing, habituation ratio, or percentage
of time spent in the corners of the arena and are unaware of any previous reports of the
effects of antidepressant drugs, strain, or sex on these measures.
We found the percentage of time spent in the center of the arena, which is
considered a measure of anxiety-like behavior, to vary with strain, sex, and SNRIX
treatment. (See Figure 2.) B6 mice spent a greater percentage of time in the center of the
arena than did D2 mice irregardless of sex or drug treatment. SNRIX had no effect on D2
mice of either sex, and B6 mice of both sexes that were administered 10 mg/kg SNRIX or
saline did not differ. On the other hand, B6 males treated with 30 mg/kg SNRIX tended
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to spend a greater percentage of time in the center of the arena, while B6 females given
30 mg/kg SNRIX tended to spend less time in the center as compared to their respective
saline controls. This suggests that chronic administration of 30 mg/kg SNRIX produces
an anxiolytic effect in B6 males but an anxiogenic effect in B6 females. We are unaware
of any previous reports on the effects of SNRIX on this measure. However, others found
that chronic fluoxetine treatment reduces center time in B6 males but is without effect in
D2 males, although the effect in B6 males was confounded with an effect on activity in
the open field (Dulawa et al., 2004). We did not find a significant effect of SNRIX on the
percentage of total distance traveled in the center of the arena. This along with the lack of
an effect of SNRIX on the total distance traveled suggests that the effect of 30 mg/kg
administration on time spent in the center of the arena is not due to differences in activity
levels. Still, further investigations would be needed to delineate causal factors behind the
strain and sex differences observed here.
Hotplate
We only found a significant effect of strain on hotplate latency, with D2 mice
exhibiting a longer latency to display a pain response than B6 mice, which concurs with
previous reports (Mogil et al., 1999). We did not find an effect of SNRIX administration.
In Swiss mice it has been reported that an acute dose of 16 mg/kg SNRIX is without
effect on hotplate latency (Ripoll et al., 2006). However, acute SNRIX administration has
been shown to increase latency in ICR mice with an estimated ED50 of 46.7 mg/kg
(Schrieber et al., 1999). Similarly, fluvoxamime and citalopram, but not escitalopram,
have been reported to increase hotplate latency when administered acutely (Schrieber et
al., 1999; Schrieber and Pick 2006). It may be the case that the doses tested in the present
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study were too low to elicit an effect. However, the lack of an effect of SNRIX in the
current study could be due to chronic as opposed to acute drug administration.
Unfortunately, acute administration was not examined here, and we are not aware of any
previous investigations of the effects of chronic administration of antidepressant drugs on
hotplate algesia.
Light-Dark
The percentage of time spent in the light half of the light-dark box is generally
recognized as a measure of anxiety-like behavior. We found a significant strain by sex
interaction. B6 males and females did not differ and spent a greater amount of time in the
light side of the apparatus than did D2 mice. Further, D2 males spent more time in the
light than did D2 females. This finding generally concurs with a previous report that male
B6 mice display less anxiety-like behavior than D2 males (Liu and Gershenfeld, 2003).
Additionally, our results indicated a trend towards an interaction between strain, sex, and
SNRIX administration, but this did not reach significance (F (2, 119) = 2.798, p = .065,
ES: f = .217; Figure 3). B6 males in the saline group spent a greater percentage of time in
the light than did any other treatment group. B6 females and D2 males did not differ,
while B6 mice of both sexes and D2 males spent more time in the light than did D2
females. Administration of SNRIX was without effect on D2 mice of both sexes as well
as B6 females. On the other hand, both doses of SNRIX tested produced an equivalent
anxiogenic response in B6 males as compared to their respective saline control. We are
not aware of any previous reports on the effects of SNRIX in the light-dark box in mice.
However, in male rats, acute or seven days treatment with 20 mg/kg SNRIX results in an
anxiolytic response, but the same dose administered for 14 days is without effect
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(Nowakowska et al., 2003). The effects of the acute administration of other
antidepressant agents on behavior in the light-dark box in mice have been previously
described; however, the reported results have been divergent. Paroxetine (Hascoët et al.,
2000) and the tricyclic antidepressant, dothiepin, (Bourin et al., 1996) have an anxiolytic
effect, but fluoxetine, imipramine, and maprotiline are without effect (Bourin et al.,
1996).
We found a significant interaction between strain and sex on the distance traveled
in the light/ dark box. B6 females traveled the greatest distance followed by B6 males and
D2 males, while D2 females traveled the least distance of all. Additionally, main effects
of strain and sex were found on the percentage of total distance traveled occurring in the
light side of the apparatus. B6 were more active than D2 mice, and males were more
active than females in the light compartment. We found no effect of SNRIX
administration on either the total distance traveled or the percentage of total distance
traveled occurring in the light.
Acoustic Startle/ Prepulse Inhibition
We found a significant interaction between strain and sex on the response to the
120 db startle stimulus. B6 males exhibited a greater response than did B6 females
followed by D2 males and females, which did not differ. This finding generally concurs
with others that have found B6 mice to display a greater startle response than D2 mice
(Paylor and Crawley, 1997; Willott et al., 2003), but where examined no effect of sex
was observed (Willott et al., 2003). Main effects of strain were found on the percentage
of prepulse inhibition of the startle response at 70, 80, and 85 db. In all cases B6 mice
exhibited a greater degree of inhibition than did D2 mice. Previous reports on strain
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differences in prepulse inhibition have varied. Our findings concur with those of one
report (Willott et al., 2003), but an opposite relation between these strains has also been
reported (Paylor and Crawley, 1997). It is possible that these differences in results are
due to differences in apparatus designs and configurations, as they vary considerably
between studies. In the present study, a main effect of sex was found on prepulse
inhibition at 80 db, but not 70 or 85 db, with males exhibiting a greater degree of
inhibition than females. Additionally, we observed a trend towards an effect of SNRIX
treatment on prepulse inhibition at 70 db (F (2, 123) = 2.832, p = .063, ES: f = .215), and
a significant effect at 80 db. (See Figure 4.) In both cases, administration of 30 mg/kg,
but not 10 mg/kg, SNRIX increased the percentage of prepulse inhibition relative to
saline controls. We are not aware of any previous reports of the effects of SNRIX on
acoustic startle or prepluse inhibition. However, serotonin agonists are generally without
effect in B6 mice tested in a MDMA disrupted prepulse inhibition paradigm (Duwala and
Geyer, 2000). Similarly, citalopram and buproprion have no effect on prepulse inhibition
and decrease the acoustic startle response, while desipramine increases prepulse
inhibition and decreases the startle response in rats treated with amphetamine (Pouzet et
al., 2005). Previous reports have indicated that the NET may play a role in acoustic startle
and prepulse inhibition in both preclinical (Yamashita et al., 2006) and clinical
populations (Quednow et al., 2004). It has previously been reported that chronic
administration of 10 mg/kg SNRIX in rats inhibits the activity of the serotonin transporter
but not the NET, while 40 mg/kg SNRIX inhibits the activity of both (Béïque et al.,
2000). If the same dose dependency exists in mice, this might provide a possible
explanation as to why in the present study we found an effect of 30 mg/kg SNRIX but not

73

10 mg/kg. These reports along with our finding suggests that further investigations into
the effects of antidepressant medications, and specifically those acting on noradrenergic
systems, on acoustic startle and prepulse inhibition are warranted.
Fear Conditioning
The measure of training suppression of activity is indicative of how successful the
training procedure was at decreasing activity relative to baseline activity prior to the
shock – tone pairings, with a lower value indicating greater suppression of activity and a
value of 1 indicating no change. We found no differences between any treatment groups
on the basis of strain, sex, or SNRIX administration for training suppression, and all
groups displayed a reduction in activity following training (M = .355, SEM = .032).
Context suppression of activity compares activity in the training context relative to the
baseline activity recorded the prior day and is indicative of the strength of the association
formed between the training context and the unconditioned stimulus (i.e. electric shock).
We found a significant effect of strain on context suppression of activity, with B6 mice
displaying less activity suggesting an enhanced memory of the context compared to D2
mice, which concurs with previous reports (Logue et al., 1997; Stiedl et al., 1999; Nie
and Abel, 2001). Additionally our finding of an interaction between strain and sex
replicates a previous report, which found no difference between B6 males and females
although D2 females displayed a greater inhibition of activity in the context than did their
male counterparts (Bolivar et al., 2001). In the present study we found SNRIX to be
without effect on context suppression of activity. We are unaware of any previous reports
of the effects of antidepressant agents on fear conditioning. However, citalopram has
been reported to reduce contextual conditioning in rats using the conditioned fear stress
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paradigm, which does not include cued conditioning (Inoue et al., 1996). As for cued
conditioning, we found a significant strain by sex interaction. B6 males and females, as
well as B6 males and D2 males, did not differ in their response to the tone. However, D2
females showed a greater reduction in activity in response to the tone than did the other
groups. Others have reported a similar interaction where females were tested (Bolivar et
al., 2001). However, reports on males alone are more varied with some finding no
differences between B6 and D2 mice (Logue et al., 1997; Nie and Abel, 2001), but
increased tone suppression of activity in B6 as compared to D2 mice has also been
observed (Stiedl et al., 1999). Such variability in findings may, in part, be due to
differences in the methods used to score behavior. For instance a number of authors have
used visual determination of freezing behavior, where as we have used an automated
system to measure general activity. Both methods have advantages; visual scoring is
more specific, but the use of an automated system increases throughput and decreases the
opportunity for experimenter error. Additionally, we have compared activity during
presentation of the tone to baseline activity in the altered context while others have
reported only activity during the presentation of the tone. Our results indicate that SNRIX
is without effect on cued conditioning; unfortunately, we are not able to compare this
with any previous reports.
Tail Suspension
We observed a large number of mice that climbed their tails during the tail
suspension test. A central principle of this test is that the stress of the procedure is
inescapable (Cryan and Mombereau, 2004), and once the animal climbs its tail, this is no
longer the case. Thus, tail climbing is problematic for the model. Little has been has been
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reported about tail climbing behavior, other than its occurrence. We therefore decided to
analyze the data collected on tail climbing using the between subject factors of the study
in a logistic regression analysis. Our analysis did not suggest that strain was predictive of
tail climbing, which is contrary to a previous report that B6 mice climb their tail more
frequently than D2 mice (Mayorga and Lucki, 2001). We did find that males were more
likely to climb their tails than females, but SNRIX treatment was without a significant
effect. Tail climbing has generally been treated as a nuisance, and some apparatus claim
to avoid the behavior by attaching the animal‟s tail to a ring rather than a metal plate.
However, our results and those of others (Mayorga and Lucki, 2001) indicate that this
trait may be influenced by genetic factors and sex, suggesting that it may be worthy of
more in depth investigation.
Overall, we did not observe an effect of strain on time spent immobile during tail
suspension. Others have reported that B6 mice exhibit more immobility than D2 mice,
although differences were small (Liu and Gershenfeld, 2003). We did not find an effect
of SNRIX on immobility. Others have reported that in mice acute administration of
SNRIX decreases immobility in the tail suspension test (Millan et al. 2001; Liu et al.,
2003; Kos et al., 2006) and the forced swim test (Redrobe et al., 1998; David et al., 2001;
Millan et al., 2001; Berrocoso et al., 2004). We are unaware of any previous reports of
the effects of chronic SNRIX administration in mice. However, in rats, administration of
SNRIX for 7 days (Nowakowska et al., 2003; Nowakowska and Kus, 2005) or 10 days
(Oliveira et al., 2004) decreases immobility, but administration for 14 days (Nowakowska
et al., 2003; Nowakowska and Kus, 2005) or 24 days (Connor et al., 2000) has no effect.
It should be noted that the reliability of our results is questionable due to the low number
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of subjects tested. In addition to dropping the data for 31.2% of the animals in the study
due to tail climbing, the data for 10 additional animals was lost due to a malfunction of
the computer used to operate the tail suspension equipment resulting in some treatment
cells being comprised of as few as four animals. Thus caution should be used in the
interpretation of these results.
Summary and Implications of Findings in Experiment 2
We have demonstrated here that the behavioral effects of chronic administration
of SNRIX in mice vary by test, strain, and sex. As has been discussed elsewhere (Dulawa
and Hen, 2005), few behavioral tests have been shown to be sensitive to chronic
administration of antidepressant drugs. Our results reinforce this notion, as we did not
find effects of SNRIX using the EZM, hotplate algesia meter, fear conditioning, or the
tail suspension test. However, we have found that treatment with SNRIX was without
effect in D2 mice, but produced an anxiolytic effect in B6 males and an anxiogenic effect
in B6 females in the open field. On the other hand, our results suggest a non-significant
trend towards an anxiogenic effect of SNRIX in B6 males, but not B6 females or D2
mice, in the light/ dark box. Lastly, we found that SNRIX produces an improvement in
the inhibition of the acoustic startle response by an 80 db prepulse regardless of strain or
sex.
The present findings have several implications for future research. Previously it
has been shown that the novelty-induced hypophagia test (Dulawa and Hen, 2005) and
the resident intruder paradigm (Mitchell and Redfern, 2005) are sensitive to chronic
administration of antidepressant drugs. Our finding that the open field and light/ dark box
are sensitive to the chronic administration of SNRIX suggests that these tests may also be
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sensitive to the chronic administration of other antidepressants. If so, this would represent
a marked improvement in efficiency, as these tests are far less time consuming to perform
than either of those previously suggested. Additionally, we have shown that the response
of B6 animals to SNRIX is dependent on sex in both the open field and light/ dark box,
which suggests that this strain may be useful for future studies on the sex dependent
effects of antidepressant agents. Further, our data indicate that B6 and D2 strains differ in
their response to SNRIX administration. This highlights the value of testing multiple
inbred strains in pharmacological research and the importance of considering background
effects when using transgenic models. Further, the difference in strain response suggests
that the BXD recombinant inbred lines may be a good choice for mapping quantitative
trait loci influencing the effects of antidepressant drugs. Lastly, the present findings
underscore the need for further investigations of antidepressant drugs that consider sex,
genetic differences, and chronic administration.
Discussion of Results of Experiment 3
Noting that there is relatively little information in the literature on age-related
behavioral differences in mice during adolescence and seeking to expand upon what is
available, we examined the B6 and D2 mice at 4, 6, and 8 weeks of age in six behavioral
models. We found almost all measures to vary with strain, and for the most part the
relations observed concur with previous reports (Logue et al., 1997; Stiedl et al., 1999;
Cook et al., 2001; Nie and Abel, 2001; Liu and Gershenfeld, 2003). Our observations
with regard to the effect of age are far more variable. Considering the standard measures
of anxiety-related behavior in the present study, we did not find an effect of age on the
percentage of time spent in the light side of the light-dark box or in fear conditioning, but
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we did find a significant strain by age interaction on the percentage of time spent in the
center of the open field and a trend towards an effect of age on the percentage of time
spent in the open quadrants of the EZM. However, these two measures depict opposite
relations between the age groups. Although not quite reaching significance (F (2, 54) =
2.971, p = .060, ES: f = .331), 8wk mice displayed more anxiety-like activity than 6wk
mice in the EZM, but the opposite was seen among B6 mice in the open field. (See
Figures 5 and 6.) Looking at the literature, it seems that age-related differences in
anxiety-like behavior differ considerably between tasks, and the patterns of variability
between tasks differ between mice and rats.
We are not aware of comparable studies of rodents in the EZM, but there are a
number of studies on age-related differences in behavior using the EPM. In mice a
relatively consistent pattern of results is seen, with most studies finding no age-related
differences during adolescence (Hefner and Holmes, 2007; Kota et al., 2007; PelegRaibstein and Feldon, 2011) or, similar to our observations in the EZM, adolescent mice
display less anxiety-related behavior than adult mice (Adriani et al., 2004; Oh et al.,
2009). On the other hand, The reports on rats in the EPM are more variable, finding
adolescents less anxious than adults (McCormick et al., 2008; Doremus-Fitzwater et al.,
2009a; Kupferschmidt et al., 2010), adults less anxious than adolescents (Elliot et al.,
2004; Lynn and Brown, 2009; Lynn and Brown, 2010), or no age-related differences
(Doremus-Fitzwater and Spear, 2007; Doremus-Fitzwater et al., 2009b; Eppolito et al.,
2010; Villégier et al., 2010).
In the open field, a converse relationship between rats and mice is seen regarding
anxiety-like behavior. The reports on mice are variable. Similar to our findings, Hefner
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and Holmes (2007) found 8wk B6 mice to display less anxiety-like behavior than 4wk or
6wk mice. However, Oh et al. (2009) found adolescent B6 mice to be less anxious than
their adult counter parts while there were no age-related differences in Swiss mice. In
contrast, reports on rats predominantly find no age-related differences in anxiety-related
behavior in the open field (Lynn and Brown, 2009; Lynn and Brown, 2010; Li et al.,
2010), but Cao et al. (2010) has found that adolescent rats are less anxious than
periadolescents or adults.
Unfortunately, we are not aware of any previous reports on age-related
differences in the light-dark box using mice, but most studies using rats have found no
age-related effects (Slawecki, 2005; Slawecki et al., 2006; Kupferschmidt et al., 2010).
However, Kupferschmidt et al. (2010) did find adolescents to display a shorter latency to
enter the light side of the light-dark box, suggesting reduced anxiety. While we did not
include this measure in our analysis, we did find that 4wk mice traveled a greater
percentage of distance in the light than did 8wk mice. While the interpretation of this
measure is nuanced, it is indicative of increased activity in an aversive environment. It
may be that in the light-dark box activity- and anxiety-related measures are more
intertwined with regard to age.
If in fact anxiety models differ in their sensitivity to age-related differences in
anxiety-like behavior between rats and mice, extrapolation of findings between species
would be tenuous, and the selection of the appropriate behavioral model would be
imperative to protecting against type II error. However, there are a number of factors that
should be considered. For instance, the number of studies examining the behavior of
adolescent rodents is limited, and the age-ranges examined between studies vary

80

considerably. Additionally, much of the available data on behavior during adolescence
comes from pharmacological studies, and many of them either do not report baseline
differences on the basis of age or analyze age groups separately. Thus, the comparisons
presented above are in places based upon estimates of the data presented. Further
complicating the issue, it seems that age-related differences may be particularly sensitive
to test and pretest conditions. For example, Slawecki (2005) found no differences
between adult and adolescent rats in the light-dark box under standard conditions but did
find age-related differences when testing was performed under bright lights or when
animals had been previously subjected to restraint stress. Unfortunately, in the end,
further research and replication will be required to disentangle the relationships between
these factors.
We also examined nociception, fear conditioning, and depression-related
behavior. We did not see any age-related effects in the hotplate algesia test. Only a few
studies have examined nociception during adolescence. Similar to our findings, ICR mice
do not display age-related differences in their latency to display a pain response in the tail
flick test or the hotplate test (Kota et al., 2007). However, adolescent and adult SpragueDawley rats do not differ in the tail flick test (Conway et al., 1998), but periadolescents
display a longer latency than do adolescents in the hotplate test (Ingram et al., 2007).
While nociception is not directly linked to anxiety-like behavior, it can be indicative of
gross abnormalities, and the finding of age-related differences in nociception during
adolescence could have implications for pain management in clinical settings.
In fear conditioning, we did not see any age related-differences in training
acquisition, conditioning to the training context, or conditioning to the cue. Similarly,
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others have found no difference in training acquisition in B6 mice (Pattwell et al., 2011;
Peleg-Raibstein and Feldon, 2011) or rats (Land and Spear, 2004; Esmorís-Arranz et al.,
2008). On the other hand, Hefner and Holmes (2007) observed 4wk B6 mice to display
more freezing at trial 4, but no differences in previous trials. With regards to conditioning
to the context, findings are variable. Some have found no age-related differences in B6
mice (Peleg-Raibstein and Feldon, 2011) and rats (Land and Spear, 2004), but others
report greater contextual conditioning in adolescent rats as compared to young adults
(Esmorís-Arranz et al., 2008). It seems that contextual conditioning may be particularly
sensitive to the exact age at which conditioning occurs. Pattwell et al. (2011) found no
differences in contextual conditioning at PND 23-27 and PND 49-70, but a deficit at
PND 29-33 and a slight deficit at PND 35-39 in B6 mice. Interestingly, when animals
were trained at PND 29-33, they showed a deficit when contextual conditioning was
tested under standard procedures, but showed normal contextual conditioning when
tested 14 days later with no additional training (Pattwell et al., 2011). The findings with
regard to conditioning to the cue are quite variable as well. Some have found no agerelated differences in B6 mice (Pattwell et al., 2011) and rats (Land and Spear, 2004), but
conflicting reports also exist finding adolescent (Hefner and Holmes, 2007) and adult
(Peleg-Raibstein and Feldon, 2011) B6 mice to both show superior conditioning to the
cue. We are not aware of any previous reports on age-related differences in fear
conditioning in mouse strains other than B6. Thus, we are unable to compare our null
findings in D2 mice directly to any other reports. Considering the differences between
inbred strains among adults, it may be the case that if additional strains were examined
strain specific age-related differences would emerge.

82

In the tail suspension test, we found no age-related differences in B6 mice, but
4wk D2 mice spent more time immobile than 6wk and 8wk D2 mice. Additionally,
looking at the progression of immobility across testing, we found that B6 mice displayed
a low initial immobility that quickly increased to a plateau. On the other hand, D2 mice,
especially in the 4wk group, showed higher initial immobility that increased more
gradually. We are not aware of any previous studies looking at age-related differences in
D2 mice in depression-related behavior, but a number of reports on B6 mice are
available. In contrast to our findings, all previous reports have found age related
differences in B6 mice in the tail suspension test (Mason et al., 2009) and the forced
swim test (Hefner and Holmes, 2007; Oh et al., 2009; Mason et al., 2009). It is not clear
why we did not see an age related effect in B6 mice, but our finding of increased
immobility in 4wk D2 mice concurs with others who have found a similar age
relationship in B6 and BALB/c mice in the TST (Mason et al., 2009) and in B6, BALB/c,
and B6x129s5 F2 mice in the forced swim test (Hefner and Holmes, 2007; Mason et al.,
2009). However, the reported age differences among mice are not entirely consistent.
Some have reported no differences in the tail suspension test in B6x129s5 F2 mice
(Mason et al., 2009) and in the forced swim test using Swiss mice (Oh et al., 2009). Still
yet, others have reported B6 adults (Oh et al., 2009) and Swiss adults (Moreira et al.,
2005) to spend more time immobile than there adolescent counterparts. None the less, the
variability between strains with regards to age-differences suggests that the development
of depression-related behavior is likely influenced by genetics, and further experiments in
this area may shed light onto the risk factors associated with pediatric/ adolescent
depression in humans.
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Conclusion
The experiments presented here are, of course, not without limitations.
Experiments 1 and 2 sought to more fully characterize the EZM by examining the acute
effects of CDZ and the effects of chronic administration of SNRIX in B6 and D2 mice. In
all actuality, this is far from a full pharmacological characterization. Our laboratory is
working to extend the findings of Experiment 1 to include two additional classes of
anxiolytics, buspirone and fluoxetine, and female animals as well. However,
unfortunately, difficulties producing mice prevented full data sets from being available.
With regards to Experiment 2, the method of drug administration is less than ideal.
Animals were injected daily. Thus, it can be assumed that an effect of handling and
injection stress was present, although experienced by all animals. Additionally, drug
administration was ceased during behavioral testing. This decision was made largely due
to the amount of drug we were provided by the pharmaceutical company and the time
constraints presented by the behavioral battery. Although we did find effects of SNRIX
administration as late as the third day of testing, it must be acknowledged that the levels
of drug on board can not be assumed to be consistent across behavioral tests. Future use
of osmotic mini pumps may well be preferable, as it would greatly diminish such
concerns. In both Experiments 2 and 3, Animals were tested on a battery of several tests
over the course of four days. We are not able to say what effect prior testing had on
subsequent testing. However, previous use of this battery in a large mutagenesis screen
suggests that phenotypes identified with sequential testing in early pedigrees are reliably
reproduced with naïve testing in later pedigrees (Cook et al., 2007). The primary benefit
of using such screens is the ability to rapidly test large numbers of animals on a relatively
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wide range of behaviors. However, it cannot be discounted that the testing history of the
animals should be considered. Lastly, in all three experiments, we have only examined
two inbred strains. It would be ideal to extend the current experiments to include
additional inbred strains, and examining the 129 strains would be of particular value
given their regular use in the generation of transgenic mice.
Looking at the experiments presented here and the literature as a whole, one of
the most striking features is the great deal of variability seen between similar tests,
animals, and drugs. For example, we found no effect of SNRIX in two measures of
anxiety-like behavior (i.e. the EZM and fear conditioning) and seemingly opposite
effects, at least in B6 males, in two other measures of anxiety-like behavior (i.e. open
field and light/ dark). While such variability is perplexing, it does seem to be the norm in
the literature on preclinical anxiety-like behavior. It is possible that different assays are
measuring unique aspects of anxiety-related behavior and particular drugs and
experimental manipulations only affect some of these. However, using factor analysis to
compare multiple measures of anxiety-like behavior often yields results that do not allow
for meaningful interpretation or suggest that each measure should load onto an
independent factor (Brigman et al., 2009; Philip et al., 2010). Ramos (2008) has noted
that the effects seen on any single measure provides only a snapshot of an animal‟s
overall pattern of behavior, and estimates of covariance between tests are highly
temporally and contextually dependent. Considering this, it is interesting that in the open
field, which is nearly four times the duration of our other measures of anxiety behavior,
we see effects of both SNRIX and age-related differences. Considering Experiment 2,
looking at only the first five minutes of open field testing, we still find the anxiolytic
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effect of SNRIX in B6 males, but the anxiogenic effect in B6 females drops out. It may
be the case that extending the test durations used in the other measures of anxiety-like
behavior would aid in detecting small to moderate effects.
Overall, the available evidence on anxiety disorders and mood disorders in
general, suggests they are the product of complex gene by environment interactions that
are further shaped across development. Murine genetic models offer a unique opportunity
to explore these relationships and address issues in the treatment of mood disorders.
However, the nature of the experimental problem requires that factors with relatively
small effect sizes be considered, which can be easily drowned out by experimental noise.
Here, attempts have been made to address this by extending the baseline data available on
anxiety-like behavior in two common inbred strains of mice, the ultimate goal being to
further our understanding of the etiology of these disorders and improve our ability to
treat them effectively.
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